Search this site

TIME World's Top HealthTech Companies 2025 TIME has released its inaugural "World's Top HealthTech Companies 2025" list, in partnership with Statista. The ranking highlights 400 companies from over 25 countries across six market segments. The companies were evaluated based on a combination of financial performance, reputation analysis, and online engagement. 24 UK HealthTech Companies Named In TIME's 'World's Top HealthTech Companies of 2025' Huma Limbic Ally Cera Caristo Diagnostics Cydar Medical Hexarad Skin Analytics Lumeon Semble Open Medical Pando Unity Accurx Birdie Closed Loop Medicine Hero Health Scan.com Fundamental XR BioBeats (a Huma company) hymia Peppy Proximie Itecho Health TIME World's Top HealthTech Companies 2025 Methodology The "TIME World's Top HealthTech Companies 2025" list, created in partnership with Statista, is based on a comprehensive methodology that evaluates companies on three key dimensions: Financial Performance, Reputation Analysis, and Online Engagement. 1. Financial Performance This dimension, which accounts for 50% of a company's total score, assesses a company's financial stability, growth potential, and operational efficiency. The evaluation is based on a mix of data sources, including: Company-submitted data via an application form. Information from the HolonIQ 1 platform. Extensive desk research. The analysis focuses on metrics like revenue, number of employees, and total disclosed funding. These are used to calculate normalized ratios to ensure a fair comparison. 2. Reputation Analysis This dimension, contributing 30% to the total score, evaluates public perception of the companies and their digital health solutions. It uses "social listening" techniques to analyze publicly available content from a variety of sources, including: News coverage Blogs Forums Social media activity The analysis focuses on a company's visibility, credibility, and sentiment, which are crucial for building trust with customers, healthcare providers, and investors. 3. Online Engagement Making up the final 20% of the total score, this dimension measures a company's digital reach and user interaction. The primary metric used is website traffic, which is analyzed over a 24-month period to determine both absolute and relative growth. This metric helps assess real-world usage, user retention, and how effectively companies are engaging with their online audience. The final list of 400 companies is a result of a scoring model that consolidates and weights the data from these three dimensions. The companies are not ranked numerically from 1 to 400, but rather categorized with "Outstanding," "Very High," or "High" performance indicators. TIME World's Top HealthTech Companies 2025 https://time.com/7318020/worlds-top-healthtech-companies-2025/ TIME World's Top HealthTech Companies 2025 Diversity of Companies The companies featured on TIME's World's Top HealthTech Companies 2025 list show a high degree of diversity in terms of their geographic location, areas of specialization, and company size. The list includes 400 companies from over 25 countries across six market segments, indicating a broad global scope. Geographic Diversity The companies on the list come from a wide range of countries, with a notable presence of firms from both established and emerging healthtech hubs. While the United States has a significant number of companies on the list, other countries are also well-represented, including: Europe: Countries like the United Kingdom, Switzerland, and Denmark are home to companies recognized for their advancements, such as Huma (UK) and BC Platforms (Switzerland). Asia: Nations like South Korea, India, and Singapore also feature prominently, with companies like AITRICS (South Korea) and Holmusk (Singapore) being included. Other regions: The list also includes companies from countries like Australia and Qatar, demonstrating the global reach of health technology innovation. Specialisation and Market Segments The list is not a single ranking but is organised into six distinct market segments, reflecting the diverse applications of technology in healthcare: AI & Data Analytics: This is a major category, with many companies leveraging AI to improve diagnostics, streamline administrative tasks, and analyze vast amounts of health data. Examples include Nym Health, which uses AI for autonomous medical coding, and VideaHealth, which applies AI to dental diagnostics. Diagnostics: This segment includes companies focused on developing innovative tools for diagnosing diseases, such as advanced imaging and predictive analytics. Medical Devices & Wearables: This category features companies that create hardware and devices for monitoring health and delivering care, like continuous glucose monitors or neuro-rehabilitation tools. Telehealth & Treatment: These companies focus on providing care remotely, from virtual consultations to digital platforms for managing chronic diseases. Health Information & Management: This segment includes firms that work on improving the administrative side of healthcare, such as electronic health records (EHRs) and patient payment systems. Prevention: This category is for companies that focus on proactive health and wellness, using technology to help individuals prevent illness and manage their well-being. Company Size and Age The list includes a mix of companies, from well-established giants to smaller, innovative startups. This diversity in size and maturity shows that innovation is happening at every level of the industry. The list features both large, publicly traded companies and newer, venture-backed startups, illustrating a dynamic and competitive landscape where new entrants can quickly gain recognition alongside industry leaders. Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising#BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

European HealthTech Market Analysis - September 2025: Transition from Fragmented Point Solutions into Critical Healthcare Infrastructure. Executive Summary The European HealthTech market, valued at an estimated $96.68 Billion in 2025, is currently navigating a period of "cautious yet discernible rebound" and strategic evolution. This shift is profoundly influenced by a reorientation of investor and corporate priorities, moving away from speculative, early-stage experimentation towards a disciplined focus on profitability and proven, scalable business models. The first half of 2025 was marked by remarkable resilience, with European digital health funding surging by 52% year-on-year to $3.4 Billion, capturing a record 26% of global digital health investment. However, this momentum entered a more selective phase in the third quarter, with initial data showing a sharp month-on-month slowdown in August. This report presents a comprehensive analysis of the forces shaping this landscape, detailing how the market is transitioning from fragmented point solutions into critical healthcare infrastructure. Key findings indicate that investment is increasingly concentrated in a "selective scale" model, favoring a few high-conviction ventures that can demonstrate clear clinical validation, robust reimbursement pathways, and defensible technology pipelines. Artificial Intelligence (AI) stands out as the dominant catalyst for this transformation, commanding higher valuations and attracting 65% of total funding in the first half of the year. Concurrently, the exit landscape has undergone a significant transformation. The IPO market remains largely subdued, posing a continued challenge for larger private equity-backed companies. As a result, M&A activity, particularly strategic acquisitions and venture-to-venture consolidation, has emerged as the primary exit pathway by volume. Furthermore, new European Union regulations, such as the EU Health Technology Assessment (HTA) Regulation and the evolving Medical Device Regulation (MDR/IVDR), are acting as powerful market forces, simultaneously streamlining processes for proven innovators while creating strategic barriers that reinforce the "flight to quality" trend. The second half of 2025 is anticipated to see accelerated deal activity as strategic buyers and private equity firms intensify their competition for high-quality, proven assets. The Resilient Rebound: H1 Momentum and Q3 Realignment Market Sizing and Overall Valuation Dynamics The European HealthTech market is demonstrating remarkable resilience in 2025, navigating a dynamic global landscape defined by economic caution and strategic re-evaluation. The market is valued at an estimated $96.68 Billion in 2025 and is projected for substantial growth, with forecasts indicating a market size of $222.22 Billion by 2030, representing an impressive 18.11% Compound Annual Growth Rate (CAGR). This growth trajectory is propelled by a confluence of factors, including persistent challenges like rising costs and an aging population, coupled with supportive EU policies and a surge in private investment, particularly within Artificial Intelligence (AI). The first half of 2025 served as a strong indicator of this resurgence. European Digital Health funding saw an impressive 52% year-on-year increase, reaching $3.4 Billion across 182 deals and capturing a record 26% share of global funding. This performance is particularly noteworthy as it runs contrary to the global digital health funding trend, which experienced a 13% year-on-year decline in the first half of the year. This defiance of global trends underscores the unique strength and investor confidence in Europe's innovation capacity.The shift towards high-conviction investments is further evidenced by a significant increase in average deal size, which reached $18.6 Million in H1 2025, a threefold increase compared to Q2 2024. Valuation metrics reflect this renewed, albeit selective, optimism. While the overall average revenue multiple for HealthTech companies has seen a decrease to 4.8x in March 2025 from a peak of 6.5x in 2023, it remains notably higher than the 3.5x average for all technology companies. This divergence underscores the sustained demand and perceived value of innovative digital health solutions. For HealthTech companies that have achieved positive earnings, Enterprise Value (EV) to EBITDA multiples are generally observed between 10-14x as of June 2025, a slight increase from the 10-12.5x range seen in 2024. Companies that align with the shift towards value-based care and demonstrate measurable cost savings and improved patient outcomes are commanding premium valuations, with multiples climbing to 5.5-7x revenue. Analysis of the Cautious Rebound: Decoding the August 2025 Funding Slowdown The characterisation of the market as "cautious" is directly linked to the shifts observed in the third quarter of 2025. While the first half of the year demonstrated robust growth, initial data for Q3 shows a significant month-on-month slowdown. August 2025 recorded just $73 Million in investment, a sharp 76% decrease from July's $298 Million. Similarly, the number of deals plummeted to 3 in August, down 84% from 19 in July. This sudden contraction in activity could be misconstrued as a market downturn, but a more granular analysis reveals it to be a logical, second-order consequence of the strategic shifts that defined the first half of the year. The research indicates that H1 2025 was dominated by a handful of large "mega-deals" valued at $100 Million or more. This trend, where seven such deals contributed to 56% of total venture capital investment in Europe, points to a clear concentration of capital. In a market where investors are increasingly moving towards a "selective scale" funding model and demanding more substantial investments, it is a natural progression for deal-making to slow following a period of intense capital deployment. Venture capital firms, having just closed a series of large, high-conviction deals, are likely in a period of operational focus, directing their attention to portfolio management and the lengthy due diligence cycles required for the next round of substantial investments. The observed August slowdown therefore represents a period of adjustment and heightened selectivity, rather than a sign of fundamental fragility. The market is not retracting; it is strategically pausing to consolidate and prepare for the next phase of disciplined growth. The Geopolitical and Economic Pressures Shaping Investor Behaviour The European HealthTech market is proving to be uniquely resilient despite facing a number of broader macroeconomic and geopolitical pressures. While the global digital health funding market experienced a 13% decline in H1 2025, Europe's market bucked the trend with a 52% surge in funding.This resilience is set against a backdrop of continued economic uncertainty, including persistent concerns over tariffs and trade tensions, which have dampened appetites for public listings and influenced overall investor caution. The overall European VC market, for instance, is down 24% from its Q2 2024 peak. Additionally, rising interest rates and increased capital costs in late 2024 and early 2025 have made financing large transactions more challenging, leading some buyers to re-evaluate or face difficulties in securing necessary funding. These financial pressures have had a notable impact on private equity firms, which are facing longer holding periods as traditional exit routes remain limited. This environment of caution and discernment has effectively forced a "flight to quality," where capital is being reallocated towards more substantial, proven investments. 3 This strategic recalibration, while contributing to a temporary slowdown in deal volume, is ultimately fostering a more mature and robust market. The New Investment Paradigm: From Hype to Health Impact The "Bigger Cheques, Fewer Bets" Thesis in Practice: The Rise of Mega-Deals A defining characteristic of the European HealthTech investment landscape in 2025 is a definitive shift away from a "spray and pray" approach towards a model of concentrated, high-conviction investment. This new paradigm, often referred to as "bigger cheques, fewer bets," is visibly manifesting through the rise of mega-deals, investments of $100 Million or more. In the first half of 2025, Europe saw seven such deals, which collectively accounted for a staggering 56% of the total venture capital investment in the region. The largest of these include Verdiva Bio's $410 Million Series A, Neko Health's $260 Million Series B and Windward Bio's $200 Million Series A. The concentration of capital in these mega-deals is not merely a funding trend; it represents a fundamental strategic repositioning of the European HealthTech ecosystem, signaling a new phase of maturity. In nascent or less mature markets, capital is often broadly distributed to test a wide array of early-stage hypotheses. The fact that Europe is now seeing a significant increase in late-stage, high-conviction investments indicates that a class of maturing companies has emerged with enough clinical validation, market traction, and demonstrable value to warrant substantial capital commitments. These companies are no longer just concepts; they are becoming critical, distribution-ready platforms for the next generation of healthcare, with investors backing proven models and clear paths to scale. The shift from fragmented point solutions to scalable, foundational infrastructure is a direct outcome of this refined investment strategy. The Shift to "Selective Scale" and the Demand for Sustainable Unit Economics The market has moved from a period of "exuberance" to a more "grounded reality," where a "flight to quality" is profoundly evident. This disciplined approach is characterised by a "selective scale" funding model. Investors are no longer captivated by aggressive expansion at all costs; instead, they are prioritising companies that can demonstrate a clear path to profitability and possess sustainable revenue models.This stands in stark contrast to the "growth at all costs" mentality of the past, particularly during the pandemic-driven boom. Companies that scaled rapidly without developing a solid, sustainable financial foundation are now becoming less attractive investment targets, which could lead to deal terminations. The Investor Playbook: Identifying Companies with Defensible Business Models and Clear Paths to Profitability The criteria for attracting significant capital have become more stringent and specific. Venture capitalists are now demanding a number of key strategic assets from companies before committing to a deal: "clinically validated datasets, clear reimbursement pathways and robust, defensible AI pipelines". The focus on profitability and proven models is simultaneously driving the commoditisation of certain digital health sub-sectors while elevating others. For example, the research indicates that B2C apps, such as symptom checkers and wellness platforms, have seen a slowdown in funding. This is because these models have often struggled to establish clear reimbursement pathways or demonstrate long-term, sustainable revenue. Furthermore, pure telehealth is noted as becoming commoditised, suggesting a crowded market with limited differentiation. Conversely, enterprise and provider-focused solutions that leverage AI to create tangible efficiencies are accelerating their growth. These are the companies that can demonstrate a "productivity premium" by shortening care pathways or reducing operational costs. The success of companies with a clear pathway to reimbursement, such as those leveraging Germany's DiGA framework, underscores the importance of this strategic approach for attracting capital and achieving commercial readiness.This creates a "winner-take-all" effect where capital flows to ventures that have successfully navigated the complex challenges of integration and reimbursement, leaving behind those with simpler, less-proven models. A defensible AI pipeline, characterised by proprietary algorithms and a deep integration into existing clinical workflows (known as "workflow lock-in"), is highly valued because it creates high switching costs and ensures a sustained revenue stream. The AI Imperative: Unlocking Value and Efficiency AI as the Primary Magnet for Capital and Strategic Interest Artificial Intelligence is the single biggest driver of valuation premiums and investor interest in the European HealthTech sector in 2025. AI-powered ventures are "unequivocally the primary magnet for both investment and M&A interest," having accounted for a staggering 65% of total funding in Europe in the first half of the year. This capital concentration is a strategic response to Europe's aging population and the growing demand for solutions that can reduce costs and increase productivity. The public sector is also a key enabler of this trend, with initiatives like the European Commission's $206 Billion InvestAI program and France's $112 Billion in committed AI investments, including a €20 Billion fund from Brookfield. What Investors Mean by "Proven" and "Defendable": The Criticality of Clinical Validation and Reimbursement Pathways The market is moving beyond a simple "AI-for-AI" narrative to a demand for solutions that demonstrate clear, tangible value and clinical efficacy. The emphasis has shifted to clinically validated solutions that can show real-world clinical impact through studies, pilot programs, or partnerships. This demand for proven results is directly linked to the need for clear reimbursement pathways, as exemplified by the success of Germany's DiGA framework, which allows certain digital therapeutics to gain national reimbursement. A "defensible" AI pipeline, in this context, implies solutions that are not only proprietary but also deeply integrated into existing clinical workflows, creating a "sticky" product with high switching costs. The Most Active Clusters and Therapeutic Areas The concentration of funding in specific therapeutic areas and clusters reflects a strategic focus on addressing system-level inefficiencies and high-cost areas. Research Solutions, driven by the promise of AI and omics related research to accelerate drug discovery, bioinformatics, and clinical trials, led the funding race, securing $938 Million in H1 2025. Medical Diagnostics ranked second, attracting $669 Million, and ranked first in deal count with 49 deals. Oncology remains the top-funded therapeutic area, with a 66% year-on-year gain, attracting $515 Million in H1 2025. This focus is a direct response to the enormous financial burden that chronic diseases like cancer and cardiovascular diseases impose on healthcare systems. Additionally, Geriatrics saw the most dramatic percentage growth among the top areas, growing a staggering 2126% quarter-on-quarter to $234 Million in the first half of the year. This dramatic growth is a clear market signal that investors are strategically targeting the long-term, demographic-driven demand for solutions that can manage chronic conditions and improve long-term home care, a direct response to Europe's aging population. Spotlight on Leading AI-Native Ventures and Their Go-to-Market Strategies A new generation of AI-driven HealthTech startups is emerging and reshaping care delivery in Europe.These companies are moving from "pilots to frontline decision support" by developing tools that address high-impact, enterprise-level problems. For instance, Estonia-based Better Medicine is using an AI-powered tool to assist radiologists in detecting kidney tumours with 99.2% precision. France's Bioptimus is building a universal AI foundation model for biology to accelerate scientific discovery for biopharma and academic institutions. German startup Elea is leveraging machine learning to digitise and interpret pathology slides, aiming to reduce turnaround times and improve diagnostic accuracy for clinical labs. Other companies like Kardi Ai, based in the Czech Republic, are enabling at-home cardiac monitoring using AI-powered wearable tech. These ventures are attracting significant capital by demonstrating tangible value and a clear path to commercial deployment, often through partnerships with established players. Exit Pathways: M&A Takes the Forefront The Subdued IPO Market: A Challenge for Private Equity-Backed Companies The digital health IPO market globally and in Europe remains sluggish and is projected to stay that way for the remainder of 2025. Despite nascent signs of revival from major US-based digital health IPOs like Hinge Health and Omada Health, the anticipated return to a robust, buoyant IPO market has not materialised. Globally, there were only 6 IPOs out of 113 total digital health exits in the first half of the year, which is only one more than in H1 2024. Public listings are widely viewed as a "challenging exit option" for large private equity-backed companies and are often considered a "channel of last resort" for assets too big to sell otherwise.Private equity firms are now facing longer holding periods for their portfolio companies due to muted public valuations and high financing costs. This is creating a backlog of mature companies that could go public once market conditions improve. The Dominance of M&A: Drivers of a Consolidation-Driven Landscape With the IPO market in a prolonged drought, M&A activity has emerged as the clear leader in digital health exits by volume. In the first half of 2025, there were 107 M&A deals recorded globally, accounting for the vast majority of exits. A significant proportion of this activity, 70%, was comprised of venture-to-venture deals.This underscores a prevailing trend towards industry consolidation, as the highly fragmented European MedTech market prompts companies to merge to achieve economies of scale and streamline operations. Private equity firms are a key driver of this M&A surge. The number of sponsor buyout deals in European healthcare spiked by a substantial 276% year-to-date in June 2025 compared to the same period in 2024.These firms are actively pursuing a "roll-up" strategy, where they invest in tech start-ups to acquire smaller rivals and build dominant conglomerates. This approach is motivated by the need to generate liquidity from portfolios when traditional IPOs are not an option. Unlike traditional private equity, VCs are infusing technology, particularly AI, into these acquired businesses to drive efficiency and margin improvements. The "String-of-Pearls" Strategy and Alternative Deal Structures The preference for M&A over IPOs, combined with the prevalent "roll-up" strategy, signals a fundamental restructuring of the market that favors scale and efficiency. Large-cap biopharma companies are adopting a "string-of-pearls" approach, acquiring early- to mid-stage innovators to strengthen their pipelines, fill capability gaps, and offset upcoming patent cliffs. This strategy is particularly active in the $1 Billion to $10 Billion deal range, with a strong focus on oncology, immunology, and rare diseases. For a startup, the exit is no longer a large, single-day public listing but rather a strategic acquisition that provides the acquirer with a new technology, a specific capability, or market share.This dynamic reinforces the need for startups to build "proven business models" and "defensible AI pipelines" that can deliver clear, tangible strategic value to a potential buyer. To mitigate risk and manage market uncertainty, there is also a growing preference for alternative deal structures such as earn-outs, royalties, licensing agreements, and co-development partnerships, particularly in biotech and diagnostics. The Regulatory Landscape: A Double-Edged Sword The EU Health Technology Assessment (HTA) Regulation: Streamlining Access and Driving Evidence A significant change in the European healthcare landscape is the application of the EU Health Technology Assessment (HTA) Regulation, which took effect on January 12, 2025. The regulation introduces Joint Clinical Assessments (JCAs), which will partially replace the separate evaluations previously conducted by each member state. Starting in 2025, JCAs are mandatory for new oncology medicines and advanced therapy medicinal products (ATMPs), with the scope expanding over time to include orphan medicinal products and all new medicines authorised by the European Medicines Agency (EMA) by 2030. This regulation is a crucial positive catalyst that directly addresses one of the key demands of investors: clear reimbursement pathways. Historically, navigating 27 different national HTA processes was a major, expensive, and time consuming barrier for HealthTech companies. The JCA streamlines this by providing a single, harmonised clinical evaluation that member states can use for national pricing and reimbursement decisions. This reduces the time and cost for market access, thereby de-risking investments in the relevant therapeutic areas and making them more attractive to capital. The Evolving Medical Device Regulation (MDR/IVDR): Compliance, Costs, and Market Impact While the HTA Regulation is a catalyst for growth, the updated Medical Device Regulation (MDR) and In Vitro Diagnostic Medical Devices Regulation (IVDR), with changes effective in 2025, present a strategic barrier that reinforces the "flight to quality" and contributes to market consolidation. The regulations have significantly tightened requirements for manufacturers, leading to more effort, higher costs, and more complex processes, particularly for small and medium-sized enterprises (SMEs). Key new requirements include information obligations for supply interruptions and extended transition periods for legacy devices. The increased costs and complexity of MDR/IVDR compliance create a significant hurdle for smaller, unproven companies. This regulatory burden makes it harder for them to compete, which in turn makes them more likely to be acquired by larger players who can better absorb the compliance costs and have established internal regulatory task forces. This environment favours well-resourced companies and strategic "roll-up" acquisitions by private equity firms, further accelerating the consolidation trend and streamlining the market. The Broader Policy Environment: EU AI Act and Public Funding Initiatives Beyond the HTA and MDR/IVDR, the broader EU policy environment is playing a significant enabling role. The implementation of the EU AI Act is providing a much-needed framework for the safe and ethical use of AI in healthcare, reducing risk for both developers and investors and paving the way for more robust AI solutions.Initiatives like the European Health Data Space (EHDS) are designed to facilitate the secure exchange of health data across the EU, which is a game-changer for AI development as it provides the foundation for training more robust AI models.Furthermore, public funding programs such as Horizon Europe, EU4Health, and national initiatives continue to be a crucial source of capital for early-stage ventures, particularly for those focused on regulated innovation like digital therapeutics and AI diagnostics. Key EU Regulatory Changes and Their Strategic Impact on HealthTech Ventures Regulation Key Changes in 2025 Strategic Implications EU Health Technology Assessment (HTA) Application of the new framework with mandatory Joint Clinical Assessments (JCAs) for new oncology medicines and ATMPs. Catalyst for Market Access: Streamlines national reimbursement by providing a single, harmonised clinical evaluation, de-risking investments in these high-value areas. Drives Evidence Generation: Reinforces investor demand for clinically validated solutions. Medical Device Regulation (MDR)/IVDR New information obligations for supply interruptions; targeted evaluation of the MDR/IVDR framework to reduce bureaucracy; extended transition periods for legacy devices. Reinforces Consolidation: Increased costs and complexity disproportionately affect SMEs, favoring larger, well-resourced players and strategic acquisitions. Strategic Barrier to Entry: Requires precise documentation and specialised regulatory expertise. EU AI Act & EHDS Implementation of the EU AI Act provides a legal framework; EHDS facilitates secure, cross-border data exchange. De-risks AI Investment: Provides clarity and reduces regulatory uncertainty, making AI ventures more attractive. Enables Innovation: The EHDS is a game-changer for training more robust AI models on a foundation of secure, shared data. Outlook and Strategic Recommendations Key Catalysts for Continued Market Growth The European HealthTech market is poised for continued activity and growth in the second half of 2025, driven by several powerful catalysts. The market is anticipated to witness an acceleration of deal activity, fuelled by intensified competition for high-quality assets between strategic buyers and private equity firms. The maturation of AI solutions is transforming them from experimental tools into critical, scalable infrastructure for healthcare, which is expected to continue to attract significant investment. Furthermore, supportive EU policies and public funding initiatives will remain a fundamental driver of growth, providing a stable foundation for early-stage ventures. Enduring Risks and Challenges Despite the positive outlook, the market continues to face a number of enduring risks and challenges. The number of venture capital deals in digital health is in a quarter-over-quarter decline, reflecting a more selective investor behaviour and lengthier due diligence cycles. This is compounded by the persistent liquidity crunch for Limited Partners (LPs), which impacts fundraising for venture capital funds overall. Furthermore, the regulatory complexity and high cost of compliance, particularly for smaller firms, remains a significant hurdle to sustained, widespread innovation. Strategic Recommendations for Investors, Founders and Corporate Entities Based on the market analysis, a number of strategic recommendations can be made for key stakeholders. For Investors: The evidence suggests that capital should continue to be deployed selectively, favouring "productivity premium" ventures that can demonstrably shorten care pathways or reduce operational costs. A deep focus on ventures with robust clinical validation, clear reimbursement pathways, and defensible AI pipelines is paramount. The ongoing consolidation trend presents a powerful opportunity to leverage M&A and "roll-up" strategies to acquire high-quality assets at attractive valuations. For Founders: The era of "growth at all costs" has ended. Founders must build their ventures with a clear, defensible path to profitability from day one. Proactively addressing and planning for regulatory compliance, such as with MDR/IVDR and the EU AI Act, is no longer optional but a prerequisite for attracting capital and achieving commercial readiness. Strategic partnerships and M&A should be considered a primary exit strategy, with a clear articulation of the strategic value the venture can bring to a larger entity. For Corporate Entities: The market presents a unique opportunity to accelerate digital transformation by acquiring innovative startups through a "string-of-pearls" M&A strategy. By leveraging new regulations like the HTA to streamline internal processes and gain a competitive edge, large corporations can absorb compliance costs and lead the consolidation trend, acquiring the technology and talent necessary to address fundamental demographic and systemic healthcare challenges. Nelson Advisors > HealthTech and MedTech M&A Nelson Advisors specialise in mergers and acquisitions, partnerships and investments for MedTech, Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk   Nelson Advisors regularly publish MedTech and Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @  https://www.healthcare.digital     We share our views with MedTech and Healthcare Technology insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb     Founders for Founders >  We pride ourselves on our DNA as ‘HealthTech founders advising HealthTech and MedTech founders.’ Nelson Advisors partner with entrepreneurs, chair persons, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk   #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide #NelsonAdvisors #MedTech   Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT   Contact Us   lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk   Meet Us at MedTech and HealthTech industry events   Digital Health Rewired > 18-19th March 2025 > Birmingham, UK  NHS ConfedExpo   >  11-12th June 2025 > Manchester, UK  HLTH Europe >  16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate >  25th June 2025, London, UK  HIMSS AI in Healthcare  >  10-11th July 2025, New York, USA Bits & Pretzels >  29th Sept-1st Oct 2025, Munich, Germany   World Health Summit 2025  >  October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit >  October 16th 2025, London, UK  HLTH USA 2025 >  October 18th-22nd 2025, Las Vegas, USA Global Health Exhibition 2025  >  October 27th-30th 2025, Riyadh, Saudi Arabia Web Summit 2025 >  10th-13th November 2025, Lisbon, Portugal   MEDICA 2025 >  November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers and acquisitions, partnerships and investments for MedTech, Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk

The Vagus Nerve Neuromodulation Ecosystem: A Comprehensive Analysis of Scientific Evidence, Market Dynamics and Investment Opportunities Executive Summary The field of vagus nerve neuromodulation (VNN) is undergoing a profound transformation, moving beyond its established applications to emerge as a cornerstone of bioelectronic medicine. While vagus nerve stimulation (VNS) has long been a recognised treatment for refractory epilepsy and treatment-resistant depression, recent technological breakthroughs and landmark clinical trial results are expanding its therapeutic reach into a wide array of chronic inflammatory, neurological and psychiatric conditions. This report provides a detailed analysis of the VNN ecosystem, synthesising the foundational science, clinical evidence, market dynamics and critical regulatory and ethical considerations. The market is characterised by a dual structure. One segment consists of established, highly regulated invasive medical devices, led by companies such as LivaNova, which continue to dominate the market share. The other, and most rapidly growing, segment is the non-invasive space, which offers a lower-risk, more accessible alternative. The recent FDA approvals of devices for stroke rehabilitation and rheumatoid arthritis represent a pivotal shift, demonstrating the technology's ability to act not just as a standalone therapy but as a sophisticated tool for enhancing recovery and modulating the body's natural anti-inflammatory pathways. The commercial landscape is defined by robust growth, fueled by significant venture capital investment in companies targeting these new indications. The presence of leading manufacturers and a developed healthcare infrastructure have positioned North America as the dominant market, while the Asia-Pacific region is poised for the fastest growth. However, the rise of direct-to-consumer (DTC) wellness products raises critical questions about regulatory oversight, product efficacy, and patient safety. The future of VNN technology points toward miniaturised, wirelessly connected, and data-driven closed-loop systems that can deliver highly personalised and adaptive therapies, promising to fundamentally redefine the management of chronic disease. Introduction to Vagus Nerve Neuromodulation and Bioelectronic Medicine The Vagus Nerve: An Anatomical and Physiological Overview The vagus nerve, designated as the 10th cranial nerve, is a central component of the autonomic nervous system. As the longest cranial nerve, it extends from the brainstem through the neck and chest to the abdomen, establishing a crucial, bidirectional communication pathway between the brain and internal organs. This nerve is predominantly composed of sensory afferent fibres, which constitute approximately 80% of its total fibres and transmit physiological information from the body's organs to the central nervous system. The remaining 20% are motor efferent fibers that send signals from the brain to the peripheral organs. This anatomical architecture allows the vagus nerve to function as a vital regulator of homeostasis, overseeing critical autonomic functions such as heart rate, blood pressure, respiration and digestion. It also plays a significant role in modulating both the endocrine and immune systems. Mechanisms of Action: The Neural and Immunological Pathways of VNS Vagus nerve stimulation (VNS) is a therapeutic approach that uses electrical impulses to modulate the activity of the vagus nerve, influencing a wide array of physiological and neurological processes. While the full mechanism of action remains an area of active research, two primary pathways have been extensively studied. Neurotransmitter Modulation and Brain Region Activation The therapeutic effects of VNS on neurological and psychiatric disorders are largely mediated through its influence on the central nervous system. Vagal afferent fibres, which are the primary target of stimulation, project upward to the nucleus of the solitary tract (NTS) in the brainstem. From the NTS, signals are relayed to various higher-order brain regions, including the locus coeruleus, the brain's main noradrenergic center, and structures within the limbic and cerebral cortices. This activation leads to a widespread release of key neuromodulators, such as norepinephrine, serotonin, dopamine, and GABA, which are fundamental to regulating mood, memory, alertness, and cognitive function. The modulation of these pathways explains the observed improvements in attention, working memory, and mood in patients undergoing VNS therapy. The Cholinergic Anti-inflammatory Pathway (CAP) A cornerstone of bioelectronic medicine is the discovery of the vagus nerve's role in controlling inflammation, a process mediated by the cholinergic anti-inflammatory pathway (CAP). Vagal efferent signals trigger the release of acetylcholine (ACh), a neurotransmitter that can bind to alpha-7-nicotinic ACh receptors (α7nAChRs) on macrophages and other immune cells. This binding action inhibits the synthesis and secretion of pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF−α), thereby suppressing the inflammatory response. This neuro immunomodulation effect is the scientific basis for the use of VNS in treating chronic inflammatory and autoimmune diseases like rheumatoid arthritis and inflammatory bowel disease. The Technology Spectrum: Invasive vs. Non-Invasive Devices The history of VNS technology is marked by an evolution from highly invasive to increasingly accessible non-invasive modalities. The origins of vagal nerve stimulation can be traced back to the 1880s, but for over a century, the technology was inherently invasive, involving the surgical implantation of an electrode and a pulse generator. This traditional approach, while clinically effective for specific conditions, presents significant barriers, including surgical risk and high cost. The late 2000s heralded a new era with the emergence of non-invasive VNS (nVNS), also referred to as transcutaneous VNS (tVNS), which was developed based on the principles of auricular acupuncture.These devices stimulate the vagus nerve through the skin, typically at the ear (auricular) or the neck (cervical). The rise of non-invasive technologies directly addresses the limitations of their invasive counterparts by offering a less risky, more convenient, and more affordable treatment option. This fundamental shift has opened the door for VNS to be applied to a wider range of conditions and to reach a broader patient population. However, the proliferation of non-invasive devices also presents new challenges, as the lack of a universally defined stimulation system and the significant variability in stimulation modalities make drawing definitive clinical conclusions more difficult. The Clinical and Scientific Landscape: Evidence and Applications Established Indications: A Review of VNS in Epilepsy and Treatment-Resistant Depression VNS has long been established as a therapeutic option for specific neurological and psychiatric disorders, with two key indications receiving long-standing regulatory approval from the U.S. Food and Drug Administration (FDA). VNS for Epilepsy: Clinical Efficacy and Long-Term Outcomes The first FDA approval for an implantable VNS device, manufactured by Cyberonics (now LivaNova), was in 1997 for adjunctive therapy in patients aged 12 and older with medically refractory partial-onset seizures. This indication was later expanded to include children as young as 4 years old. VNS is considered a treatment option for the approximately one-third of epilepsy patients whose seizures are not adequately managed by anti-seizure medications. While VNS does not typically cure epilepsy or stop seizures completely, its goal is to reduce the number, length, and severity of seizures. A large study involving 454 patients showed a 50% or greater reduction in seizures in 37% of patients after one year, with continued benefits over time. Technological advancements have led to newer models, such as LivaNova’s AspireSR, which can automatically deliver stimulation when a sudden increase in heart rate, a potential sign of an impending seizure, is detected. VNS for Treatment-Resistant Depression: A Nuanced Evidence Base In 2005, VNS was FDA-approved as an adjunctive long-term treatment for adults with chronic or recurrent depression who have failed to respond to four or more adequate antidepressant treatments. However, the scientific evidence for its efficacy in depression is inconsistent, a point of critical importance in clinical analysis. A key randomised controlled trial with 235 patients reported no statistically significant differences between the active intervention and placebo groups. This finding stands in contrast to the results from uncontrolled, open-label studies and some meta-analyses, which suggest that VNS provides improving benefits that can build over time, sometimes for up to two years. This inconsistency in the literature, combined with the fact that only a small percentage of patients in the initial FDA-approved study showed significant improvement after one year, underscores the complexity of this application. This therapeutic approach is generally considered only after other conventional treatments, including medication and psychotherapy, have proven unsuccessful. Breakthroughs in Neuromodulation: Expanding Therapeutic Horizons In recent years, VNS has demonstrated significant promise in new therapeutic areas, moving beyond its traditional scope to address a wider range of medical conditions. These breakthroughs have solidified VNS's position as a versatile tool in bioelectronic medicine. Stroke Rehabilitation: The Vivistim System and the VNS-REHAB Trial MicroTransponder, Inc. has pioneered an FDA-approved VNS system, Vivistim, for use in stroke rehabilitation. This device represents a fundamental shift in the application of neuromodulation. Instead of a standalone treatment, it functions as a "therapy enhancer," working in tandem with high-repetition, goal-oriented rehabilitation exercises to improve neuroplasticity. The pivotal VNS-REHAB trial, a triple-blinded randomised controlled study, demonstrated that patients who received paired VNS therapy regained two to three times more upper-extremity function compared to those who received rehabilitation alone. The long-term analysis of this trial, published in the journal Stroke, showed that these clinically meaningful improvements in motor impairment and functional activity were maintained for at least one year and, in some cases, for up to three years after therapy completion. This provides compelling evidence for the technology's long-term benefit for chronic ischemic stroke survivors. Rheumatoid Arthritis: SetPoint Medical's Neuroimmune Breakthrough A landmark FDA approval in July 2025 marked the first-ever neuroimmune modulation device for adults with moderate-to-severe rheumatoid arthritis (RA). Developed by SetPoint Medical, this implantable, jellybean-sized device works by automatically delivering one-minute electrical stimulations to the vagus nerve per day, leveraging the body’s innate anti-inflammatory pathways. The device offers a non-pharmaceutical treatment alternative for patients who have not found adequate relief from existing therapies like biologics or disease-modifying anti-rheumatic drugs (DMARDs). The RESET-RA study, a key clinical trial, demonstrated remarkable efficacy, with three-quarters of participants achieving symptom relief without additional therapy and an average 60% improvement in tender and swollen joint counts over 12 months. This approval signifies a paradigm shift, recognising the brain’s role in managing inflammatory diseases and paving the way for similar devices to treat other immune-mediated conditions, such as inflammatory bowel disease. Headaches and Migraines: Evidence for Non-Invasive Solutions Non-invasive VNS has also received FDA approval for the treatment of certain primary headaches. For example, electroCore's gammaCore device is cleared for the treatment of cluster headaches and migraines.The device works by blocking pain signals and is held against the skin of the neck. While non-invasive VNS can be an effective non-pharmacological option for the acute treatment of migraine attacks, evidence for its prophylactic use is more mixed, with some reviews citing a lack of relevant benefits and poor patient adherence to the protocol. The Frontier of Research: Emerging and Investigational Areas The therapeutic potential of VNS continues to be explored in a wide array of emerging and investigational applications. These studies are extending the technology's reach into new frontiers of neuroscience and bioelectronic medicine. Post-Traumatic Stress Disorder (PTSD): A pioneering Phase 1 clinical trial conducted by researchers at the University of Texas at Dallas and Baylor University Medical Center yielded highly promising, albeit preliminary, results for patients with treatment-resistant PTSD. The study involved pairing a small, dime-sized wireless VNS implant with a standard 12-session prolonged exposure therapy regimen. The findings exceeded expectations, with all nine participants losing their PTSD diagnosis and reporting clinically significant improvements that persisted for at least six months. While highly encouraging, researchers have cautioned that these results are preliminary and have stressed the need for larger, double-blind, placebo-controlled trials to confirm the efficacy and safety of this approach. Chronic Inflammatory Diseases: Building on the success of VNS in treating rheumatoid arthritis, a number of studies are investigating its potential for other inflammatory and autoimmune disorders. A key area of research is inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. Researchers at the Bionics Institute are developing an implantable device that stimulates the abdominal branch of the vagus nerve, which may help to prevent the recurrence of Crohn's disease while avoiding the undesirable side effects, such as vocal cord issues, associated with stimulating the cervical vagus nerve. Other Conditions Under Investigation: The body of research into VNS continues to grow, with studies exploring its potential in a diverse range of other conditions. These include post-COVID fatigue, working memory improvement, insomnia, and neuro developmental disorders like ADHD and autism spectrum disorder. VNS is also being studied for its effects on glucose metabolism and its potential role in neurodegenerative diseases. The success of VNS in stroke and rheumatoid arthritis, where it is combined with existing therapies or targets a specific physiological pathway, illustrates a broader trend. VNS is evolving from a primary, stand-alone treatment into a more sophisticated, integrative technology that enhances the efficacy of other interventions. In stroke, the device is explicitly "paired" with high-repetition physical therapy to catalyse neuroplasticity, thereby amplifying the therapeutic effect of the exercises themselves. Similarly, in rheumatoid arthritis, the technology is integrated with the body's innate anti-inflammatory pathways to provide a non-immunosuppressive treatment. This shift in value proposition, from being a "seizure reducer" to a "therapy enhancer," suggests that the future of VNN lies in its role as a sophisticated biological interface. FDA-Approved VNS Devices by Indication and Approval Date Manufacturer Device Name Indication Approval Date Cyberonics (now LivaNova) VNS Therapy Refractory Epilepsy July 1997 Cyberonics (now LivaNova) VNS Therapy Treatment-Resistant Depression July 2005 electroCore, Inc. gammaCore Migraine/Cluster Headache 2017-2019 MicroTransponder, Inc. Vivistim System Stroke Rehabilitation 2021 SetPoint Medical SetPoint System Rheumatoid Arthritis July 2025 Summary of Key Clinical Trials in VNS Trial Name Indication Phase Sample Size Key Findings VNS-REHAB Stroke Rehabilitation Pivotal 108 Paired VNS led to 2-3 times more upper-extremity function improvement. Gains were maintained for at least one year. RESET-RA Rheumatoid Arthritis Pivotal 242 75% of participants achieved symptom relief; 60% average improvement in tender/swollen joint counts over 12 months. PIVOT for PTSD PTSD Phase 1 9 100% of participants lost their PTSD diagnosis. Benefits persisted for at least six months. PRESTO Migraines (Acute) RCT 10 Italian sites nVNS significantly increased the probability of being pain-free or having mild pain after 2 hours. Market Analysis: Sizing, Companies and Investment Trends Global Market Overview and Forecast The global market for vagus nerve stimulators is undergoing robust growth, driven by an expanding range of applications and rising demand for non-pharmacological treatment options. Market forecasts, however, show a significant range, reflecting the market’s fragmentation and the differing scopes of what is being measured. For example, while some reports project the VNS market to reach approximately 1.3 billion dollars by 2032, others provide a much higher forecast of 2.3 billion dollars by the same year, with an even more bullish projection of 21.3 billion dollars by 2030. These discrepancies are not necessarily contradictory; they likely stem from whether the forecast includes the burgeoning and less-regulated direct-to-consumer wellness segment in addition to the traditional, highly-regulated medical device market. Despite these variances, a consistent market narrative emerges. The growth is fuelled by a confluence of factors, including the increasing prevalence of chronic diseases, a growing geriatric population, and continuous technological advancements. While implantable devices are projected to contribute the highest share (66.3% in 2025), non-invasive devices are the fastest-growing segment, with a projected CAGR of 7.8%.The epilepsy segment remains the largest application area, expected to hold 38.3% of the market in 2025. Global Vagus Nerve Stimulators Market Forecast Source Base Year Value Forecast Year Forecasted Value Compound Annual Growth Rate (CAGR) Coherent Market Insights USD 667.4M (2025) 2032 USD 1,293.1M 9.9% Fortune Business Insights USD 505.2M (2018) 2032 USD 2,294.3M 11.4% Polaris Market Research USD 8.59B (2021) 2030 USD 21.3B 10.6% Competitive Landscape: Profiles of Leading Companies and their VNS Products The VNS market features a mix of established leaders and innovative newcomers, each focusing on distinct product types and applications. LivaNova PLC: A dominant player in the implantable VNS space, LivaNova's VNS Therapy system has long been the primary choice for treating epilepsy and depression. The company’s established clinical efficacy, robust global distribution channels, and technological advancements like the AspireSR device have secured its market leadership. MicroTransponder, Inc.: This company has distinguished itself with its innovative Vivistim Paired VNS System, specifically developed for stroke rehabilitation. By focusing on a novel, high-growth application, MicroTransponder has created a new standard of care in the stroke recovery continuum, securing significant venture capital investment and forming strategic partnerships with leading hospital systems. SetPoint Medical: SetPoint has emerged as a key innovator in the burgeoning neuroimmune modulation space. Its SetPoint System for rheumatoid arthritis is the first-of-its-kind, leveraging the anti-inflammatory properties of the vagus nerve to treat an autoimmune condition. The company's recent capital raises signal a strong investor confidence in its technology and commercialisation strategy. electroCore, Inc.: A leader in non-invasive VNS, electroCore's gammaCore device offers a medication-free treatment option for primary headaches. Its non-invasive approach provides a compelling alternative to traditional pharmaceuticals, addressing a large patient population seeking less-invasive solutions. Emerging and Consumer-Facing Companies: The landscape also includes a growing number of companies operating in the non-invasive space. Tivic Health is a health technology company focused on bioelectronic medicine, and it is collaborating on a pilot study to test a novel non-invasive VNS approach. Vielight offers a non-invasive photo biomodulation device for home use, marketed for general wellness. These companies highlight the expansion of VNS technology beyond traditional medical settings into the consumer market. The Investment Ecosystem: Recent Funding and Key Investor Insights The VNN market is attracting substantial capital, with recent funding rounds concentrated on companies with proven clinical efficacy in novel indications. This indicates a strategic shift among investors, who are increasingly looking beyond the saturated epilepsy and depression markets toward new frontiers. SetPoint Medical's significant capital raise of 140 million dollars, co-led by Elevage Medical Technologies and Ally Bridge Group, is a prime example of this trend, as the funds are designated to support the commercialisation of its neuroimmune modulation therapy for RA. Similarly, MicroTransponder's successful 65 million dollar Series F financing round, spearheaded by US Venture Partners, underscores investor confidence in the Vivistim System’s clinical and commercial viability for stroke care. These investments suggest that the most promising opportunities lie in products that can demonstrate a clear clinical benefit and a defined regulatory pathway for new, high-growth applications. Notable VNS Company Investment and Funding Rounds Company Product Indication Funding Type Amount Key Investors SetPoint Medical SetPoint System Rheumatoid Arthritis Series C, Series D $140M Elevage Medical Technologies, Ally Bridge Group, Northwell Health, SPRIG Equity MicroTransponder Vivistim System Stroke Rehabilitation Series F $65M US Venture Partners, Longitude Capital, Gilde Healthcare Regional Dynamics: North America's Dominance and Asia-Pacific's Rapid Growth The global VNS market is heavily concentrated in North America, which has consistently held a dominant market share. In 2018, the region accounted for 44.48% of the market, driven by the strong presence of major medical device manufacturers like LivaNova and electroCore. The region's advanced healthcare infrastructure, high patient awareness of new treatment options, and, most importantly, favourable reimbursement policies for conditions like epilepsy and depression, have collectively fuelled its market leadership. While North America remains the largest market, the Asia-Pacific region is emerging as a critical growth engine, projected to exhibit the highest compound annual growth rate. This rapid expansion is attributed to the rising incidence of neurological and psychiatric disorders in countries like China and Japan, which is linked to aging populations and changing lifestyles. The increasing healthcare awareness and rising investments in research and development in these regions are expected to further propel market growth in the coming years. Regulatory, Safety, and Ethical Considerations Navigating the Regulatory Landscape: FDA Classification and Approval Pathways Medical devices in the United States are subject to the oversight of the FDA, which classifies them into three risk-based categories: Class I, II, and III. The regulatory control increases with each class. Implantable VNS devices, such as those used for epilepsy and depression, are considered high-risk Class III devices. They require a rigorous Premarket Approval (PMA) application, which necessitates extensive clinical data to demonstrate both safety and efficacy before commercial distribution is permitted. To collect this data, companies must first obtain an Investigational Device Exemption (IDE) to allow for clinical studies. This stringent process ensures that high-risk devices are thoroughly vetted, providing a crucial layer of public health protection. A Critical Distinction: Medical Devices vs. General Wellness Products A significant distinction exists between VNS devices that are regulated as medical devices and those that are marketed as general wellness products. The former, like LivaNova's VNS Therapy, must meet the strict requirements of a PMA and are approved for specific medical indications such as epilepsy. In contrast, a number of non-invasive neurostimulation devices, such as the Vagustim device, are classified as general wellness products under the FDA's guidelines. This classification allows them to bypass the extensive and costly FDA medical device approval process. They are instead marketed with vague claims related to stress relief, relaxation, or improved sleep, without making any specific assertions about treating or curing a disease. This distinction creates a regulatory divergence where the same underlying technology is subject to vastly different levels of oversight, presenting a fundamental tension between market accessibility and public safety. Comparison of Regulatory and Ethical Oversight for VNS Devices Category Medical Device General Wellness Product Regulatory Body U.S. Food and Drug Administration (FDA) Not FDA-regulated as a medical device Primary Pathway Premarket Approval (PMA) or 510(k) No FDA approval required for marketing Example Device LivaNova VNS Therapy, SetPoint System Vagustim, Vielight Vagus Key Marketing Claims Treat, diagnose, cure, mitigate a disease (e.g., "reduces frequency of seizures") Promote "stress relief," "relaxation," or "enhanced focus" Primary Ethical Concerns Surgical risks, long-term safety, contraindications Insufficient regulation, questionable efficacy, misleading advertising, privacy Risks and Patient Safety: A Review of Side Effects and Contraindications While VNS is generally considered safe and well-tolerated, both invasive and non-invasive forms carry specific risks and potential side effects. Invasive VNS Risks: The surgical procedure to implant the device carries standard surgical risks, including pain at the incision site, infection, and, in rare cases, vocal cord paralysis or Horner's syndrome. Post-implantation, patients may experience side effects such as voice changes, hoarseness, coughing, throat pain, or shortness of breath. Non-Invasive VNS Risks: Non-invasive devices are typically associated with minimal side effects when used within common parameters. However, some reports have noted potential safety issues, such as ear canal inflammation, vertigo, and fever, at higher stimulation intensities. General Contraindications: Both implantable and non-invasive VNS devices have contraindications. For example, VNS is contraindicated in patients who have had a vagotomy or who have pacemakers or defibrillators due to the risk of interference. Medical professionals stress the importance of thorough psychiatric screening for patients and ensuring they are able to operate the device safely. Ethical Considerations in the Direct-to-Consumer Market The rise of direct-to-consumer (DTC) neurostimulation products brings with it a host of ethical considerations. This market, largely unregulated by the FDA as a medical device space, operates with different standards of evidence and oversight. The most frequently cited ethical concerns include insufficient regulation and a lack of proven efficacy and quality. Marketing for these devices is often accused of being misleading, with vague or exaggerated claims that may entice vulnerable populations seeking solutions for complex health issues. The absence of a healthcare professional in the purchasing process can also compromise informed consent, as consumers may not be fully aware of potential risks, contraindications, or more effective alternative treatments. While proponents argue that the DTC model improves access and consumer autonomy, the potential for physical harm and the burden on the healthcare system from mismanaged conditions remain significant points of concern. Future Outlook and Strategic Recommendations Key Trends Shaping the Future of VNS Technology The trajectory of vagus nerve technology is being shaped by several key trends that point toward a future of more personalised, precise, and integrated therapeutic interventions. Miniaturisation and Wireless Connectivity: Devices are becoming dramatically smaller and more user-friendly. Researchers at the University of Texas at Dallas, for example, have developed a wireless VNS implant that is roughly the size of a dime. This miniaturisation will enable less invasive surgical procedures and new applications, making the technology more appealing to a broader patient population. The integration of wireless technology also facilitates remote device programming and monitoring, which improves patient management and reduces the need for frequent clinic visits. Integration of AI and Wearable Tech: The next wave of innovation is centered on developing "smart," closed-loop systems. Unlike first-generation devices that delivered fixed stimulation, new devices will be able to sense physiological signals in real-time and automatically adjust their stimulation parameters. LivaNova's AspireSR, which can detect an impending seizure based on heart rate changes, is an early example of this trend. The future will likely see VNS devices integrated with wearable biosensors and AI-powered algorithms to create a truly personalised, data-driven therapeutic experience. This shift moves VNS beyond a simple treatment modality and positions it as a key element of precision medicine. Targeted and Personalised Therapies: As the understanding of the vagus nerve's specific branches and their functions deepens, innovation will focus on more targeted stimulation to achieve maximum therapeutic effect with minimal side effects. The Bionics Institute's research into stimulating the abdominal vagus nerve for Crohn's disease exemplifies this trend, aiming to achieve the desired anti-inflammatory effect while avoiding the side effects associated with cervical stimulation. Strategic Recommendations for Investors, Innovators and Clinicians Based on this comprehensive analysis, the following strategic recommendations are offered to key stakeholders in the VNN ecosystem. For Investors: It is prudent to prioritise companies with robust, peer-reviewed clinical evidence, particularly from pivotal randomised controlled trials, as this data is essential for navigating the rigorous FDA approval process. The significant venture capital flowing into companies with novel, high-growth applications, such as stroke rehabilitation and rheumatoid arthritis, suggests that these emerging areas present the most attractive investment opportunities. It is also critical to understand the stark difference between the highly-regulated medical device market and the burgeoning consumer wellness market, as the regulatory and liability risks, as well as the valuation models, are fundamentally different. For Innovators: The path to market leadership lies in developing advanced, closed-loop systems that can provide personalised, data-driven therapy. Future devices should integrate biosensors and artificial intelligence to optimise treatment protocols for individual patients. A focus on miniaturisation and novel anatomical targets, such as the abdominal vagus nerve, will be key to expanding therapeutic indications and minimising side effects, creating significant competitive advantages. For Clinicians: While VNS offers a promising therapeutic avenue, it should be approached as an adjunctive therapy, not a universal cure. Clinical decisions should be guided by a careful review of the evidence base for each specific indication, which can be nuanced and, in some cases, inconsistent. For implantable devices, thorough patient screening, including psychiatric evaluations, is essential. With the proliferation of non-invasive DTC products, clinicians must also be prepared to educate patients on the differences between FDA-approved medical devices and general wellness products to ensure patient safety and to manage expectations regarding efficacy. Nelson Advisors > HealthTech and MedTech M&A Nelson Advisors specialise in mergers and acquisitions, partnerships and investments for MedTech, Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish MedTech and Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views with MedTech and Healthcare Technology insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech founders advising HealthTech and MedTech founders.’ Nelson Advisors partner with entrepreneurs, chair persons, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #MedTech #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT Contact Us lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us at MedTech and HealthTech industry events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Global Health Exhibition 2025 > October 27th-30th 2025, Riyadh, Saudi Arabia Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers and acquisitions, partnerships and investments for MedTech, Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

Nelson Advisors LLP: Profile of a European Healthcare Technology M&A Specialist I. Executive Summary: Navigating the "Nelson" Landscape Nelson Advisors LLP, a UK-based firm, is explicitly and exclusively focused on providing mergers and acquisitions (M&A) advisory services within the healthcare technology sector across the United Kingdom, Europe, and North America. The firm’s core value proposition is rooted in a distinctive "practitioner-led" approach. This model is a direct function of the synergistic partnership between its two co-founders, whose professional backgrounds combine extensive corporate finance expertise with direct, hands-on experience in building, scaling, and successfully exiting healthcare technology businesses. Nelson Advisors LLP A. Core Business and Specialisation Nelson Advisors LLP positions itself as a specialised M&A advisory firm with an exclusive dedication to the dynamic healthcare technology (HealthTech) sector. Its core focus encompasses a range of sub sectors, including MedTech, Digital Health, Health IT, Consumer HealthTech, Healthcare Cybersecurity, and Healthcare AI companies. The firm’s geographic scope is explicitly stated to cover the UK, Europe, and North America, indicating a transatlantic reach for its specialised services. This concentration on a single, high-growth vertical allows the firm to cultivate a deep level of industry-specific knowledge and a network that generalist M&A firms typically cannot match. B. Business Model and Service Offerings The firm's business model is a direct reflection of its founders' practitioner-led approach. They frame their advisory services around a "Build, Buy, Partner, Sell" framework, a model born from their personal experience in the industry. The firm provides a comprehensive suite of M&A services, including buy-side and sell-side advisory, corporate divestitures, and roll-up strategies. These transaction-focused services are complemented by strategic advisory offerings, such as go-to-market strategies and international expansion guidance. The average client engagement is noted to last between three and six months, suggesting a business model centred on specific, time-bound, and project-based transactions rather than long-term, retainer-based advisory.This structure indicates an optimisation for a streamlined, project-oriented revenue stream. C. Official Corporate Information Nelson Advisors LLP is a newly established entity with a recent incorporation date. It was formed as an active limited liability partnership (LLP) on April 7, 2025, a crucial detail for any party conducting due diligence. The firm's official company number is OC456267, and its registered office address is Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT. Official Corporate Details of Nelson Advisors LLP Data Point Detail Official Name NELSON ADVISORS LLP Company Number OC456267 Corporate Status Active Limited Liability Partnership Date of Incorporation April 7, 2025 Registered Address 76-78 Portland Place, London, United Kingdom, W1B 1NT Leadership and Foundational Expertise: The Practitioner-Led Advantage The primary asset of Nelson Advisors LLP is the combined and synergistic experience of its two co-founders, Lloyd Price and Paul Hemings. Their backgrounds are distinct yet complementary, creating a unique advisory offering for the HealthTech market. A. The Founding Partners: Lloyd Price and Paul Hemings Lloyd Price is a co-founder with a strong background in technology entrepreneurship and strategic business development. His career includes senior roles at major internet companies such as Yahoo! Europe and Badoo/Bumble from 2000 to 2012. His most significant achievement is the founding and successful exit of Zesty, a HealthTech business that was acquired by Induction Healthcare Group PLC in 2020. Beyond his entrepreneurial ventures, he serves as a Non-Executive Director for various UK digital health companies, mentors students, and regularly guest lectures at prestigious university business schools like University College London, Oxford University, and Cambridge University. He is a founding member of the "Digital Healthcare Council" and has served as a judge for industry awards, including the Digital Health Pitchfest Awards. His experience provides the firm with deep operational and strategic insight into the lifecycle of a HealthTech company. Paul Hemings, the other co-founder, brings a decade of global M&A and capital-raising expertise. His corporate finance career includes senior investment banking advisory roles at Credit Suisse, where he advised on over $50 billion in M&A transactions and over $40 billion in equity/financing deals across numerous countries. He also possesses his own entrepreneurial experience, having founded and exited two early-stage companies. His educational background includes an honours degree in Economics from Queen's University and an MBA from London Business School. Hemings’s profile provides the institutional rigor and financial acumen necessary to navigate complex corporate transactions and effectively engage with institutional investors and large corporate acquirers. B. A Synergistic Partnership and Unique Value Proposition The combined professional history of Price and Hemings forms the foundation of the firm's practitioner-led advantage. Together, they have built, scaled, and exited four HealthTech businesses since 2012, in sectors ranging from patient engagement to medical device cybersecurity. The synergy between their skill sets is a key differentiator. Hemings provides the classic, institutional-grade M&A expertise that is essential for structuring complex deals, while Price brings the hands-on operational reality and strategic market insight of a successful founder. This fusion allows the firm to effectively "bridge the gap between innovative HealthTech startups and the demands of institutional investors and large corporate acquirers". The firm's ability to provide guidance that is not only financially sound but also operationally and strategically informed is a direct consequence of its founders' dual expertise. Market Position, Thought Leadership Nelson Advisors LLP is as a leading authority in the European HealthTech M&A landscape through a combination of focused expertise and public engagement. A. Industry Engagement and Thought Leadership The firm maintains a robust content strategy to demonstrate its deep market knowledge. Its blog features a range of specialised articles on topics such as "HealthTech Mergers & Acquisitions" and "Partnerships & Investments". Recent blog posts include in-depth analyses of trends like "Digital MSK Europe" and "The European HealthTech M&A Landscape," as well as research on "HealthTech M&A valuation multiples" and fundraising processes for early-stage companies. This content directly signals the firm's hyper-specialisation and its commitment to providing valuable market intelligence. The founders’ external engagements such as guest lecturing at prominent business schools and serving as judges for industry awards, further solidify their standing as respected thought leaders within the European HealthTech community. Analysis of Thought Leadership and Industry Credibility Activity Description Blog & Market Research Publishes articles and market reports on HealthTech M&A, valuations, and industry trends. Awards Judging Co-founder Lloyd Price has served as a judge for the Digital Health Pitchfest Awards (2022, 2023) and the HealthInvestor Awards (2024, 2025). Guest Speaking Both founders regularly guest lecture and speak at leading business schools, including UCL, Oxford, Cambridge, and London Business School. Industry Networks Co-founder Lloyd Price founded "The Future Health community" and was a founding member of the "Digital Healthcare Council". Conclusion: Distinctive and credible advisory firm Nelson Advisors LLP is a distinctive and credible advisory firm that stands apart from the multitude of unrelated entities sharing its name. The firm's value is not derived from a long corporate history under its current name but is instead inextricably linked to the extensive and synergistic experience of its founding partners, Lloyd Price and Paul Hemings. By combining hands-on entrepreneurial experience with institutional-grade corporate finance expertise, the firm offers a highly specialised, practitioner-led advisory service tailored to the unique complexities of the healthcare technology sector. While the firm’s recent incorporation date means its corporate track record is short, the founders’ individual track records provide a strong foundation for its credibility. For a company or investor operating in the HealthTech and MedTech space, this specialised approach and leadership pedigree are compelling assets. The firm's proactive self-differentiation and robust thought leadership further demonstrate its strategic positioning. As a result, Nelson Advisors LLP emerges as a highly credible partner for those seeking an advisory firm that possesses not only a nuanced understanding of financial mechanics but also the strategic and operational acumen to navigate the full lifecycle of a healthcare technology business. Nelson Advisors > HealthTech and MedTech M&A Nelson Advisors specialise in mergers and acquisitions, partnerships and investments for MedTech, Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish MedTech and Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views with MedTech and Healthcare Technology insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech founders advising HealthTech and MedTech founders.’ Nelson Advisors partner with entrepreneurs, chair persons, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #MedTech #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide #DefenceTech #Nelson #Advisors Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT Contact Us lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us at MedTech and HealthTech industry events around the Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Global Health Exhibition 2025 > October 27th-30th 2025, Riyadh, Saudi Arabia HealthTechX 2025 > 4th November 2025, London, UK Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MedTech Malta 2025 > 12th-14th November 2025, Valetta, Malta MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers and acquisitions, partnerships and investments for MedTech, Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

The European Private Equity Playbook for Value Creation in HealthTech & MedTech: Navigating the 2025 Landscape and Beyond Executive Summary: A Strategic Blueprint for Success The European HealthTech and MedTech sectors are undergoing a profound transformation, moving from a fragmented, early-stage ecosystem to a mature, consolidating landscape ripe for sophisticated private equity (PE) strategies. This report serves as a strategic blueprint for PE firms aiming to capitalise on this evolution. The analysis reveals that the European digital health market has emerged as a global leader in funding growth, propelled by a strategic pivot towards fewer, larger transactions and a disproportionate focus on artificial intelligence (AI) and high-growth therapeutic areas like oncology and research solutions. This new reality demands a proactive and operational-centric "playbook," moving beyond traditional financial engineering to a model of deep, hands-on value creation. The central premise of this playbook is that success is contingent on a multi-faceted approach. Firms must first target a foundational "platform" asset in a high-growth vertical, which can then be scaled through a "buy-and-build" strategy of strategic bolt-on acquisitions. A critical component of this strategy is the recognition that Europe's stringent regulatory frameworks, such as the Medical Devices Regulation (MDR) and the General Data Protection Regulation (GDPR), should not be viewed as mere hurdles but as sources of competitive advantage. A company that demonstrates robust compliance and clinical validation is a de-risked and highly attractive asset. Finally, a clear exit strategy must be developed from the outset, whether through a trade sale to a strategic buyer or a well-executed Initial Public Offering (IPO). This report provides a comprehensive guide to navigating these complexities, offering data-driven strategies for due diligence, operational excellence, regulatory navigation, and exit optimization in the dynamic European market. Chapter 1: The Evolving European HealthTech and MedTech Market 1.1 Current Market Dynamics and Investment Climate The European healthcare technology market has distinguished itself as a global leader in innovation and investment, demonstrating remarkable resilience and accelerated growth. In 2024, the region’s digital health sector recorded a striking 27% year-over-year (YoY) funding increase, significantly outpacing the global funding recovery of 5.5%. This robust growth trajectory is a clear signal of Europe's attractiveness to investors, who are increasingly recognising its potential as a powerhouse for innovation. A key driver of this funding success is the substantial rise of "mega-deals"—transactions valued at $100 million or more. In Europe, these high-value deals nearly doubled year-on-year in 2024, accounting for 37% ($1.74 Billion) of the $9.4 Billion invested globally through such transactions. This surge indicates a profound shift in market maturity. Instead of a proliferation of smaller, early-stage investments, capital is now being concentrated in fewer, larger, and more transformative transactions. This trend is further underscored by the dynamics observed in 2025, where a notable 87% spike in European HealthTech M&A deal value occurred alongside an 8% decline in deal count. This "quality over quantity" dynamic signals that the market is primed for a sophisticated PE "buy-and-build" strategy, where firms can acquire a significant platform company and scale it through strategic consolidation. This market shift is being directly fuelled by a confluence of factors, including a substantial amount of unallocated private equity capital, often referred to as "dry powder," which totals USD $2.5 Trillion globally. This significant capital pool is actively seeking high-growth opportunities, with PE engagement in European healthcare surging by a staggering 276% in deal value in 2025 alone. This robust activity positions PE not merely as a market participant but as a primary driving force, creating a competitive environment for acquiring desirable assets. The European market, in particular, has seen momentum provided by investments in biopharma services and consumer health, contrasting with the North American focus on provider services and healthcare IT. This divergence highlights the need for a targeted, Europe-specific investment playbook. 1.2 Dominant Technological and Therapeutic Trends Investment capital is not being deployed indiscriminately; it is being channeled into specific technological and therapeutic areas poised for hyper-growth. Artificial intelligence (AI) has emerged as the central axis of this investment, taking centre stage in Europe's digital health evolution. In 2024, AI-driven ventures captured a remarkable 58% of the region’s total digital health funding, highlighting the transformative potential of AI in everything from diagnostics and treatment personalisation to operational streamlining. Investors are no longer interested in basic data analysis; they are targeting companies that develop "explainable AI models," integrate multiple data sources (such as genomics and wearable data), and provide tools that clinicians can trust and seamlessly adopt. From a therapeutic perspective, funding is heavily concentrated in sectors addressing critical global healthcare needs. Oncology ($810 Million) and Research Solutions (TechBio, $4.77 Billion) have emerged as the top sectors for venture capital, collectively capturing nearly half of all deployed capital. This intense focus on high-impact areas underscores a strategic approach to investment that seeks to solve major clinical challenges. Furthermore, opportunistic investors are identifying emerging niches, such as digital obesity care platforms, which saw a 40% increase in global funding in 2024, driven by the rise of GLP-1 medications.These trends indicate that a successful PE strategy must be closely aligned with these dominant technological and clinical shifts, focusing capital on proven, high-growth areas. European Digital Health Funding Trends 2024-2025 Metric 2024 Digital Health Funding 2025 HealthTech M&A YoY Growth 27% (Digital Health Funding) 87% (Deal Value) Global Comparison Outpaced global funding recovery (5.5% YoY) - Mega-Deal Contribution 37% of global mega-deal value - Capital Concentration Fewer but larger deals (8% decline in deal count alongside value spike) - Top Funded Sectors AI (58% of total funding), Oncology ($810M), TechBio ($4.77B) - European HealthTech/MedTech Market Benchmarks Metric Valuation Range Context & Nuance Revenue Multiples 4-6x revenue (Q1 2025 avg. 4.8x) Valuations for high-growth, innovative solutions Premium Multiples 5.5-7x revenue For companies with strong data monetisation or value-based care models EV/EBITDA Multiples 10-14x EBITDA (as of June 2025) For HealthTech companies that have achieved positive earnings Technology Premium 17.1x earnings Valued on average compared to 14.9x industry average Chapter 2: The Value Creation Playbook: From Due Diligence to Operational Excellence 2.1 Advanced Due Diligence in a Complex Ecosystem In an environment of intensifying competition and regulatory scrutiny, the traditional due diligence model is no longer sufficient. A comprehensive PE playbook for Europe must incorporate advanced, multi-faceted diligence that goes far beyond financial auditing to encompass operational, technological, and regulatory risks and opportunities. This process begins with rigorous pre-acquisition audits of a target entity's financial transactions, documentation, coding, and billing practices to proactively detect existing fraud, waste, and abuse (FWA) issues. This is a critical step in de-risking a potential acquisition and setting a foundation for a robust compliance framework. Furthermore, a thorough technology and AI governance assessment is paramount.This involves evaluating the target's technology infrastructure for cybersecurity vulnerabilities and post-acquisition integration risks. As governments promulgate new laws and regulations related to AI governance, PE firms must also assess the target's AI oversight to ensure compliance and avoid future liabilities. Finally, a comprehensive pre-acquisition audit of a company’s regulatory compliance, particularly with frameworks like the Medical Devices Regulation (MDR), the In Vitro Diagnostic Regulation (IVDR), and the General Data Protection Regulation (GDPR), is essential. Instead of viewing these frameworks as obstacles, this diligence process should frame them as a source of competitive advantage, as a compliant company is inherently more valuable and globally marketable. 2.2 Post-Acquisition Operational Value Levers Once an acquisition is complete, the true work of value creation begins. This is not a passive process of capital deployment but an active, hands-on endeavor centered on operational excellence. The most effective strategy in the current market is the "buy-and-build" approach, which is perfectly suited to the market's consolidation trend. This involves acquiring a foundational "platform" company and then executing a series of strategic bolt-on acquisitions to expand its market share, service offerings, and geographic reach. A significant portion of global M&A activity in digital health, 70%, involves venture-to-venture transactions, which highlights the widespread adoption of this strategy among firms seeking to strengthen their market positions. Driving commercial excellence and market penetration is another key lever. This involves guiding portfolio companies to optimise their go-to-market strategies by enhancing the digital customer experience and leveraging technology to enable personalized services and automated claims processes. By investing in companies that develop user-friendly platforms, telehealth consultations, and AI-driven health management tools, PE firms can capture significant market share and pave the way for a profitable exit. Finally, optimising operations, supply chain, and general and administrative (G&A) functions is crucial. Value creation is an interconnected process that requires cross-functional collaboration. Firms must guide portfolio companies to leverage technology, such as AI, to enhance supply chain reliability and operational efficiency, thereby resetting their cost base and driving continuous cost optimisation. Chapter 3: Strategic Deal Sourcing: Navigating a Mature Market In a competitive market characterised by high valuations and abundant capital, a reactive approach to deal flow is a recipe for mediocrity. A successful PE firm must employ a proactive and strategic deal sourcing strategy to identify and secure high-quality assets. The optimal target for a PE investment is the "often-overlooked middle tier" of companies. These firms are mature enough to benefit from PE guidance and expertise, and while they may not be on a trajectory to reach billion-dollar valuations, they hold significant potential for double-digit growth. This middle tier presents a unique opportunity, as these assets can be acquired at reasonable valuations and then scaled through operational improvements and strategic bolt-on acquisitions. A critical and increasingly important source of high-quality deal flow is corporate divestitures. The European HealthTech sector is experiencing a significant wave of corporate carve-outs, where large corporations are proactively shedding non-core or lower-growth assets to reinvest in high-growth, technologically advanced areas, particularly those related to AI. This trend creates a robust supply of assets that might be undervalued within their larger organisational structures but hold significant potential for a PE firm. By identifying and acquiring these carve-out opportunities, a PE firm can leverage its operational expertise to transform a non-core business unit into a highly efficient, standalone entity or a platform for a broader roll-up strategy. This market dynamic, combined with the presence of specialized and hybrid funds that blend traditional venture capital (VC) with PE models, requires PE firms to be agile and creative in their sourcing efforts, often engaging in strategic partnerships to gain a first look at promising assets. Chapter 4: Navigating the European Regulatory and Compliance Landscape The European regulatory environment is both a significant challenge and a source of profound competitive advantage. While frameworks like the Medical Devices Regulation (MDR) and the In Vitro Diagnostic Regulation (IVDR) can be complex and burdensome, they also serve as a strict filter, selecting only companies with the highest added-value and most robust compliance frameworks. For a PE firm, this means that a target company that has successfully navigated these regulations is a de-risked asset with a clear pathway to market. Europe's high standards for safety and data protection, epitomised by the GDPR, are not simply rules to be followed but a strategic asset that can create a significant competitive moat. A company that is validated in the EU is inherently more trustworthy and globally marketable. In the post-acquisition phase, compliance should be treated as an active value creation lever, not a cost center. PE firms should leverage technologies like data analytics and AI to measure, monitor, and enhance compliance, operational efficiency, and clinical quality. This proactive approach helps to mitigate fraud, waste, and abuse (FWA) risks and aligns with the Office of Inspector General's (OIG) updated guidance, which now expects compliance functions to have a greater role in auditing and monitoring the quality of care and patient safety. Furthermore, the broader regulatory ecosystem presents both risks and opportunities. Intensifying scrutiny of PE-backed healthcare entities, state-level transactional hurdles (as seen in US examples), and a renewed focus on fraud enforcement by the Department of Justice (DOJ) necessitate robust and well-documented compliance programs at the portfolio company level. Conversely, EU initiatives like the International Procurement Instrument (IPI), which excludes Chinese suppliers from competing for public medical device contracts, could create a more favourable environment for domestic and EU-based firms. Chapter 5: Strategic Pathways to Exit The successful execution of a PE playbook culminates in a well-planned and highly profitable exit. For a firm operating in the European HealthTech and MedTech sectors, the primary exit paths are a trade sale to a strategic buyer or an Initial Public Offering (IPO). The decision between these two paths is influenced by a number of factors, including the company's size, growth trajectory, and market position. A trade sale to a strategic buyer is a common and highly effective exit strategy, particularly for assets that can be integrated into a larger corporate structure. This strategy is fuelled by a strong buyer-side demand from both PE firms and strategic acquirers for capital-light, scalable assets like AI-driven diagnostics and digital therapeutics. Corporations are actively seeking to acquire innovative technologies and platforms to complement their own portfolios and drive digital transformation. This market dynamic creates an ideal environment for PE firms to divest non-core units that they have optimised and scaled. Alternatively, an IPO presents a viable and lucrative exit path, especially for companies that have achieved significant scale and market leadership. The operational and strategic enhancements made by a PE firm, such as driving commercial excellence, consolidating the market through bolt-on acquisitions and establishing a robust compliance framework, are precisely the qualities that attract public market investors. The track record of firms like HBM Partners, with over 60 successful trade sales and IPOs, demonstrates that a well-executed playbook can lead to either of these outcomes. The key is to prepare the company for a potential IPO from the very beginning of the investment period, ensuring the financial controls, governance, and growth story are compelling enough for a public offering. Chapter 6: Spotlight on Key Players and Case Studies To fully understand the principles of this playbook, it is essential to examine real-world applications by leading PE firms and their strategic partners. The approach taken by Nordic Capital exemplifies a successful operational strategy centred on sustainable growth and differentiation. A notable example is its nine-year ownership of Sunrise Medical, a global leader in assistive mobility solutions. During this period, Nordic Capital’s focus was not just on financial returns but on a deep commitment to "innovation, operational excellence and platform investments". This hands-on approach expanded Sunrise Medical's market position and ultimately led to a successful sale, demonstrating how patient capital and strategic operational guidance can create lasting value. Similarly, the role of a strategic legal partner cannot be overstated in the complex European landscape. The case of Fieldfisher’s advisory role in Adtec Healthcare’s $12 Million funding round highlights this partnership model. Fieldfisher provided comprehensive support, navigating the complexities of cross-border investment and regulatory requirements while aligning the transaction with the company's long-term growth strategy. This example underscores how a strategic legal partner provides value beyond traditional legal services, acting as a critical ally in advancing transformative healthcare technologies. Conclusion & Outlook: The Path Forward The European Private Equity Playbook for HealthTech and MedTech is defined by a central principle: success in this evolving market is not a matter of capital alone, but of strategic, operational, and regulatory agility. The data confirms that Europe is a high-potential, high-value investment landscape, with funding growth outpacing the global average and a strategic shift towards larger, more impactful deals. The firms that will thrive in this environment are those that adopt a proactive, hands-on approach, targeting mature "platform" assets in high-growth verticals and scaling them through disciplined "buy-and-build" strategies. For 2026 and beyond, the outlook suggests continued market consolidation driven by the confluence of PE dry powder and a strategic wave of corporate divestitures. AI and data-driven assets will continue to attract premium valuations, and the companies that can ethically leverage patient data and demonstrate seamless interoperability will be highly valued. The most successful firms will be those that view Europe's complex regulatory environment, from MDR/IVDR to GDPR, not as a hurdle but as a strategic asset that creates a competitive moat. By investing in operational excellence, prioritising robust compliance, and actively managing their portfolios through a well-defined value creation playbook, private equity firms can unlock significant value and position themselves for success in this dynamic and promising market. Nelson Advisors > HealthTech and MedTech M&A Nelson Advisors specialise in mergers and acquisitions, partnerships and investments for MedTech, Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish MedTech and Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views with MedTech and Healthcare Technology insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech founders advising HealthTech and MedTech founders.’ Nelson Advisors partner with entrepreneurs, chair persons, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #MedTech #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT Contact Us lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us at MedTech and HealthTech industry events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Global Health Exhibition 2025 > October 27th-30th 2025, Riyadh, Saudi Arabia Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers and acquisitions, partnerships and investments for MedTech, Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

The Symbiotic Relationship Between MedTech and DefenceTech Executive Summary The relationship between medical technology (MedTech) and defence technology has historically been characterised by an ad hoc, one-directional flow of innovation, often described as a "spin-out" effect where military research unexpectedly finds civilian applications. However, a contemporary analysis reveals a more complex, mutually beneficial, and increasingly institutionalized symbiosis. This interdependence is no longer a matter of serendipitous discovery but a deliberate, two-way exchange driven by a shared imperative: the optimisation of human performance and survival in high-stakes, resource-constrained environments. The MedTech industry, defined by its focus on devices and systems for diagnosis, treatment, and health improvement, and the defence sector, focused on national security and operational advantage, are now inextricably linked through a convergence of core technologies. Artificial intelligence, robotics, advanced materials, and cybersecurity are inherently dual-use, with applications that directly parallel the needs of both industries. For example, an AI system that triages patients in an emergency room can be re-engineered to prioritise casualties on a battlefield, while a portable diagnostic tool developed for bioterrorism can be adapted for point-of-care testing in a civilian clinic. This report examines this dynamic relationship through the lens of both historical and contemporary innovation flows, from the "spin-out" of battlefield trauma care to the "spin-on" of commercial medical systems for military use. It highlights the pivotal role of government agencies and public-private consortia, such as the Defense Advanced Research Projects Agency (DARPA), the Defense Innovation Unit (DIU), and the Medical Technology Enterprise Consortium (MTEC), in formalizing and accelerating this collaboration. The analysis concludes by addressing the profound ethical and policy challenges posed by this integration, particularly the "dual-use dilemma" and the potential "militarization of medicine." This framework provides a comprehensive overview for strategic investors, policymakers, and industry leaders seeking to understand the landscape and identify opportunities within this critical, evolving symbiosis. Introduction: Defining the Interdependent Domains A. The Scope of Medical Technology (MedTech) Medical technology, or MedTech, is a broad and rapidly evolving field dedicated to the development and application of technologies that diagnose, monitor, treat, and alleviate sickness or disease, ultimately improving human health and quality of life. The discipline is distinct from the broader category of "Healthcare Tech," as it specifically pertains to the technologies, products, and services directly used for patient care. The scope of MedTech is vast, encompassing a wide spectrum of devices, from low-risk, everyday items like medical gloves, bandages, and thermometers to highly sophisticated, high-risk systems. The latter includes advanced imaging machines such as magnetic resonance imaging (MRI) and computed tomography (CT) scanners, as well as complex implantable devices like pacemakers and insulin pumps. The industry is a manufacturing success story, notable for its significant investment in research and development, which fuels a constant cycle of innovation and improvement. MedTech's primary objective is to enhance the accuracy and timeliness of healthcare, reduce hospital stays, and provide patients with the means to live longer, healthier, and more productive lives. B. The Scope of Defence Technology Defence technology involves the research, design, and implementation of military systems, weapons, and strategic defence mechanisms to further national security. It is the application of technology for use in warfare, encompassing systems that are often distinctly military in nature due to their lack of useful or legal civilian applications. The field spans a diverse range of areas, including advanced engineering, artificial intelligence, and cybersecurity, all aimed at protecting military assets and counteracting enemy attacks.Core components of defence technology include aerospace and avionics for military applications (e.g., fighter jets), radar and surveillance systems for early warning, and ballistic missile defence systems. The industry is heavily reliant on a competitive advantage in key sectors like microelectronics, telecommunications, and software development, and it is a major driver of innovation. The overarching goal of defence technology is to reduce risk, enhance operational efficiency and gain an information advantage on the battlefield. C. The Thesis of Symbiosis The relationship between MedTech and Defence Tech is not a simple linear process but a complex, interdependent symbiosis. While historical precedent often points to military innovations "spinning out" into the civilian medical sector, a contemporary view reveals a deliberate, two-way exchange of technologies and methodologies. This mutualistic relationship is increasingly formalized through dedicated government programs and public-private partnerships. The foundational link between these two seemingly disparate domains is the shared challenge of optimising human performance and ensuring survival under duress. Whether on a remote battlefield or in a chaotic disaster zone, the requirements are strikingly similar: the need for rapid, accurate diagnostics, remote care capabilities, durable and portable equipment, and systems that can function with limited resources and minimal human intervention. This shared set of operational constraints acts as a powerful catalyst for cross-sector innovation, accelerating the development of technologies that would otherwise take decades to mature. This report will demonstrate that this symbiosis has evolved from an ad hoc phenomenon into a strategic imperative for both the defence industry and the global healthcare market. The Flow of Innovation: From Defence to Medicine (The "Spin-out" Effect) The defence sector has long served as a high-pressure crucible for medical innovation. The life-and-death stakes and the urgent, resource-constrained environment of the battlefield compel rapid development and testing of technologies. This unique context accelerates the research and development cycle in a way that civilian markets cannot, producing solutions that are exceptionally durable, efficient, and reliable under extreme duress. These battlefield-tested innovations have subsequently "spun out" to become foundational pillars of modern civilian medicine. A. Foundational Advancements in Trauma Care Military conflicts have historically been a primary driver of major innovations in treating life-threatening injuries, leading to the development of protocols and devices now standard in civilian emergency rooms and trauma centers. A historical example is the work of Major Walter Reed in 1900, who led the Yellow Fever Commission to discover that mosquitoes carried the disease, saving countless lives. The advancements in trauma care from this period forward have been profound, with survival rates for wounded soldiers increasing from 4% in World War I to 50% in World War II. Specific innovations that have crossed over include tourniquets, hemostatic agents (quick-clotting bandages), and the widespread adoption of damage control resuscitation (DCR) protocols. DCR, which began as a research area at the U.S. Army Institute of Surgical Research, is now a protocol widely used in civilian trauma centers to improve survival rates after severe injury. B. Advancements in Prosthetics and Assistive Technologies The ongoing need to rehabilitate severely injured service members has consistently driven the military to push the boundaries of assistive technology. Innovations in prosthetic limb technology, developed to provide more functional and lifelike limbs for amputees, have greatly benefited their civilian counterparts. For instance, research funded by the Department of Veterans Affairs has led to the development of percutaneous osseointegrated prosthesis (POP implants), which are surgically anchored to an individual's remaining thigh bone. Patients who receive these implants have reported that the devices feel like they are a part of them, representing a significant quality-of-life improvement over traditional prosthetics. Similarly, research funded by DARPA has focused on restoring the sense of touch for amputees through advanced prosthetic technology. C. Remote Operations and Diagnostics The military's need for remote command, control, and treatment has been a significant driver for technologies that enable care from a distance. Defence-funded research into tele-operated robotic systems, originally intended for remote operations in extreme environments, has had a profound influence on modern surgical platforms like the Da Vinci system.These systems allow for minimally invasive procedures with greater accuracy and reduced recovery times in civilian hospitals. Similarly, the need to quickly detect and respond to biological threats has been a priority for defence agencies, leading to advancements in medical diagnostics. Portable diagnostic tools originally designed to detect bioterrorism agents have been adapted for rapid civilian disease detection, such as point-of-care COVID-19 antigen tests and portable blood analysers. D. Crossover of Foundational Technologies Beyond direct medical advancements, several general-purpose defence technologies have become fundamental to civilian healthcare. The Global Positioning System (GPS), initially developed for military navigation, is now critical for emergency response systems and telemedicine platforms, enabling providers to locate patients and coordinate care. Radar technology, developed for military detection during World War II, laid the groundwork for medical imaging techniques, such as ultrasound and certain scanning methods. One of the most compelling examples of this spin-out effect is the EpiPen, a device for treating anaphylaxis, which originated from a military-developed auto-injector designed to administer nerve agent antidotes to soldiers. The following timeline illustrates the historical flow of innovation from the defence sector to medicine, highlighting key milestones in this long-standing relationship. Year Innovation/Technology Defence Origin Civilian Medical Application 1900 Yellow Fever Commission U.S. Army research into tropical diseases Public health, disease prevention and control WWII Radar Technology Detection of enemy aircraft and ships Medical imaging (ultrasound, etc.) 1970s Auto-injector (CombiPen) Administration of nerve agent antidotes EpiPen for anaphylaxis treatment 1990s Damage Control Resuscitation (DCR) U.S. Army Institute of Surgical Research Standard protocol in civilian trauma centers 1990s Da Vinci Surgical System Research into remote robotics for space/military Minimally invasive surgery with greater accuracy 2000s Global Positioning System (GPS) Military navigation for operations Emergency response, telemedicine, patient tracking 2020 Portable Diagnostic Tools Detection of bioterrorism agents/chemical warfare substances Point-of-care antigen tests (e.g., for COVID-19) The Flow of Innovation: From Medicine to Defence (The "Spin-on" Effect) The reverse flow of innovation, where technologies and methodologies from the civilian MedTech sector are adopted by the military, represents a strategic shift in defence procurement. This "spin-on" effect is a reflection of the defence sector's recognition that the speed and scale of innovation in the commercial MedTech industry can address critical operational gaps more effectively and efficiently than traditional, bespoke military R&D. The military is leveraging civilian technologies to enhance warfighter health and performance, provide advanced field diagnostics, and support remote operations. The military faces the dual challenge of a rapid pace of technological change and immense budget pressures. The traditional, lengthy, and expensive military procurement process for custom-built equipment struggles to keep up with the fast-moving innovation cycles of the commercial sector. By actively seeking and "spinning on" commercial technologies, military agencies can bypass some of these limitations, acquiring proven, and often more cost-effective, solutions more rapidly. This approach also serves to strengthen the national security innovation base by integrating new, non-traditional companies and their expertise into the defence ecosystem. A. Enhancing Human Systems and Warfighter Health The military is increasingly adopting commercial MedTech to optimise the human system and enhance the health and readiness of service members. This includes the use of off-the-shelf technologies that would not have been developed specifically for military use. For instance, the military is exploring the use of continuous glucose monitoring technology for soldiers with Type 1 diabetes, which allows for consistent tracking of glucose levels without frequent blood draws. The U.S. Army’s Telemedicine & Advanced Technology Research Center (TATRC) is actively exploring how commercial innovations like mobile apps that connect patients to behavioural healthcare providers can improve military healthcare, reflecting a deliberate effort to leverage civilian advances. B. Point-of-Care and Field Diagnostics Civilian medical diagnostic tools are being leveraged to enhance military operational capabilities, particularly in the fields of disease surveillance and rapid threat detection. Point-of-Care Ultrasound (POCUS) is a major disruptive diagnostic and decision-support technology that has rapidly made inroads into military field care.AI-assisted POCUS applications are being deployed to improve image acquisition and analysis, requiring less operator training and providing medics with lab-grade insights in austere environments. In the fight against infectious diseases, a concern for both military and civilian populations, the Naval Medical Research Center has successfully treated a drug-resistant infection with bacteriophage-based therapy. This innovation, while originating from military research, is poised to offer an alternative to antibiotics for complex wound infections, a growing global health problem. C. Dual-Use Robotics and Unmanned Systems The military is increasingly repurposing commercial drones and robotic platforms for medical applications, a powerful example of the "spin-on" effect. Unmanned aerial vehicles (UAVs), initially developed for surveillance and combat, are now being explored for casualty evacuation and medical supply delivery. This use of autonomous drones is reducing the risks to human operators who would otherwise be exposed in dangerous areas. A prime example of this convergence is DARPA's Medics Autonomously Stopping Hemorrhage (MASH) program, which aims to use robots guided by advanced sensors and AI to locate and stop severe internal bleeding with limited human assistance. These autonomous systems are being developed to stabilise injured personnel for extended periods, providing crucial time for evacuation to hospitals. This program represents a deliberate effort to integrate robotics and AI from the broader technology ecosystem into a military-medical context. The Convergence of Core Technologies: The Dual-Use Matrix The symbiotic relationship between MedTech and Defence Tech is most evident in the shared technological foundation upon which both industries are building their futures. Several core technologies are inherently dual-use, serving as the primary nexus for innovation. The following analysis and accompanying table illustrate how these technologies are solving parallel, high-stakes problems in both domains. A. Artificial Intelligence and Machine Learning Artificial intelligence (AI) is the quintessential dual-use technology, with a transformative potential that is equally applicable to saving lives and enhancing destructive capabilities. In the MedTech sector, AI-powered diagnostics leverage machine learning algorithms to detect tumours and analyse medical imaging with greater accuracy than human review alone. AI-driven predictive models are also used by public health organisations to monitor and forecast the spread of infectious diseases. In the defence sector, AI is revolutionising decision-making and operational strategies. It is used for real-time threat detection, autonomous navigation, and the analysis of vast datasets to predict threats on the battlefield.The parallel application of AI is most clearly seen in battlefield triage systems, which use algorithms to rapidly assess and prioritise casualties, providing medics with critical, real-time decision support. B. Advanced Materials and Additive Manufacturing Both the MedTech and defence industries require materials that are lightweight, durable, and possess high-performance properties like energy absorption and resistance to fracture. The MedTech industry uses advanced materials like titanium alloys for dental and bone implants, capitalising on their excellent osteo-integration properties and rust-free long life. The Defence Research and Development Organisation (DRDO) in India, for example, has developed titanium-based implants for both military and civilian use, a clear example of dual-purpose innovation. In defence, additive manufacturing (3D printing) and advanced materials are used for the rapid production of complex, mission-specific components, reducing reliance on traditional supply chains. These technologies also enable the development of new, high-strength materials that improve the functionality and durability of military equipment. C. Cybersecurity and Secure Networks The increasing reliance on networked systems has made cybersecurity a critical, shared concern for both industries. The MedTech sector is facing growing regulatory pressure to secure patient data, electronic health records, and networked medical devices against cyberattacks. This requires new product life-cycle management processes to identify vulnerabilities and remediate risks. For the defence sector, cybersecurity acts as the digital shield for sensitive military networks, command-and-control systems, and critical infrastructure. Both domains are integrating next-generation cybersecurity protocols that leverage AI and advanced encryption to ensure data integrity and system reliability in the face of sophisticated cyber warfare. D. Robotics and Autonomous Systems Robotics are at the heart of the future of both MedTech and defence. In MedTech, micro-robots with dexterous manipulation capabilities are being developed for applications such as targeted drug delivery, clearing clogged blood vessels, and microsurgery. These systems allow surgeons to access hard-to-reach anatomy and perform delicate interactions with tissues to reduce invasiveness. In defence, autonomous combat drones and robotic platforms are used for high-risk operations like surveillance, intelligence gathering and bomb disposal, reducing the risk to human personnel. The intersection of these two applications is seen in the use of autonomous drones for casualty extrication and the development of robotic platforms for remote surgical procedures on the battlefield. The Dual-Use Technology Matrix Technology MedTech Application Defence Tech Application Artificial Intelligence (AI) AI-powered diagnostics for imaging analysis, predictive models for disease outbreak monitoring, and automated triage systems for patient care. AI-driven warfare strategies, autonomous drones for surveillance and combat, real-time threat detection, and AI-powered battlefield triage. Advanced Materials & Additive Manufacturing 3D-printed prosthetics and customized implants, titanium alloys for bone and dental implants, and novel biomaterials for tissue regeneration. Rapid prototyping of complex components, on-demand production of mission-specific parts, and the development of high-impact-resistant materials for vehicles. Cybersecurity Securing electronic health records, protecting networked medical devices against attacks, and ensuring data integrity in telehealth platforms. Protecting sensitive military networks, command-and-control systems, and critical infrastructure from cyberattacks. Robotics & Autonomous Systems Micro-robots for targeted drug delivery and microsurgery, robotic surgical platforms (e.g., Da Vinci system), and automated systems for laboratory analysis. Autonomous combat drones, robotic bomb disposal units, and unmanned systems for logistics and casualty evacuation in high-risk zones. Collaborative Ecosystems and Key Facilitators The transition from a coincidental "spin-out" model to a deliberate symbiosis is underpinned by the emergence of organisations and partnerships specifically designed to bridge the MedTech and defence sectors. These entities act as the primary engines of collaboration, formalizing the transfer and co-development of dual-use technologies. A. Government and Military R&D Agencies Key government agencies play a pivotal role in this ecosystem. The Defence Advanced Research Projects Agency (DARPA) is a crucial driver of dual-use innovation, tackling national security challenges with solutions that have broad civilian applications. DARPA's Medics Autonomously Stopping Hemorrhage (MASH) program, for example, is developing sensor-guided robots for autonomous surgical intervention on the battlefield, a technology with clear implications for civilian pre-hospital trauma care. Similarly, its Detect It with Gene Editing Technologies (DIGET) program, which provided rapid and precise diagnostic capabilities for COVID-19, began as a defence-focused effort on infectious disease testing. The Defense Innovation Unit (DIU) represents a powerful example of the "spin-on" effect being institutionalised at a federal level. DIU's mission is to accelerate the adoption of leading commercial technology for military use, specifically focusing on "human systems" and other dual-use capabilities. By working directly with the commercial technology ecosystem, DIU provides a faster and more agile pathway for proven civilian technologies to be integrated into military operations. This institutionalised approach is not unique to the U.S. In India, the Defence Research and Development Organisation (DRDO) operates the Defence Bio-Engineering & Electro Medical Laboratory (DEBEL), whose mission is explicitly dual-purpose. It develops life support equipment and biomedical devices for service combatants while also exploring the utilisation of "spin-off technologies for civilian application," such as the production of titanium-based implants for both military and civilian patients. B. Public-Private Partnerships and Consortia Public-private partnerships and consortia are critical for bringing together diverse stakeholders to advance dual-use technologies. The Medical Technology Enterprise Consortium (MTEC) is a prime example, advancing medical innovation by leveraging military-civilian partnerships. MTEC connects a network of over 600 members, including small and large businesses, federal agencies, and academic institutions, to expedite the development of cutting-edge medical technologies. Its use of a flexible "Other Transaction Agreement" (OTA) model allows for faster project awards and technology development than traditional procurement methods, fostering a robust collaborative environment. C. The Commercialisation and Technology Transfer Process The process of commercializing defence-funded research for civilian markets is a formal effort. NASA's Technology Transfer Program, while not strictly military, provides a parallel model for how defence technologies are "liberated" for broader use. Through publications like NASA Tech Briefs and Spinoffs, the program documents technologies that have been successfully commercialised, from memory foam and freeze-dried food to cochlear implants and CMOS image sensors.This deliberate process of identifying and scaling dual-use technologies is a vital component of the symbiotic relationship. Key Organisations and Their Collaborative Models Organisation Purpose & Focus Collaborative Model DARPA Addresses urgent national security challenges by developing high-risk, high-reward technologies with potential for "strategic technological surprise." Funds and manages programs with both defence and civilian applications, often involving private companies, universities, and government labs. DIU Accelerates the adoption of leading commercial technology into the military and bolsters the national security innovation base. Partners with commercial technology companies (many of whom are new to the DoD) to prototype and field "dual-use capabilities" at commercial speeds. DRDO (DEBEL) Develops protective, life-support, and biomedical devices for military combatants and explores the utilization of "spin-off technologies for civilian application." Operates as a government-led R&D laboratory with a dual-use mandate, transferring technology for both military and civilian production. MTEC Advances medical innovation by fostering partnerships between military, academia, and private industry to improve military and civilian health. Acts as a consortium that uses a flexible OTA to expedite development, bringing together a broad ecosystem of stakeholders to address common needs. Ethical, Legal, and Societal Implications The profound interdependence between MedTech and defence technology introduces significant ethical, legal, and policy complexities that must be carefully navigated. The inherent dual-use nature of core technologies, coupled with the blurring of professional lines, creates a new set of challenges for researchers, policymakers, and society at large. A. The Dual-Use Dilemma The most significant challenge is the "dual-use dilemma," which refers to the ethical paradox of technologies designed for benevolent purposes that can be repurposed for harm. This is particularly acute for technologies like AI and biotechnology, where the same scientific information intended to save lives can be used to threaten a population. For instance, a medical AI system that can detect anomalies in a human body during an MRI scan could be re-engineered to analyse surveillance imagery for predictive targeting. A pharmaceutical that non-invasively increases alertness for military personnel could be used to keep a warfighter awake for days on end, blurring the line between medical support and performance enhancement. This intrinsic duality complicates governance and demands careful consideration of the potential for misuse. B. The "Militarisation of Medicine" Debate The historical and contemporary relationship between military and medical practices has led to a debate over the "militarisation of medicine." This concept explores how the professional identities and practices of medical officers are shaped by military culture and the unique demands of warfare. While military medicine has undeniably driven a focus on empirical and observational models that have influenced civilian practice, the integration of modern defence technologies introduces new questions. When a medic's tools include autonomous drones for casualty evacuation or AI-powered triage systems, the lines between the role of a "caregiver" and a "warfighter" begin to blur. This can create ethical conflicts regarding patient loyalty, data use, and the potential for a medical intervention to serve a tactical rather than purely therapeutic purpose. C. Data Privacy and Algorithmic Bias The convergence of technologies also raises significant concerns about data privacy and algorithmic bias. Both the MedTech and defence sectors handle vast amounts of sensitive data—patient health records in one case and classified intelligence in the other. When these datasets are used to train AI and machine learning systems, there is a risk of data breaches and the potential for algorithmic bias to emerge. For example, a bias in a medical AI system could lead to inaccurate diagnoses for certain populations, while a bias in a military AI could lead to flawed decision-making on the battlefield. These concerns demand urgent attention to ensure the reliability and ethical application of these powerful technologies. D. Policy and Regulatory Frameworks Developing effective policy and regulatory frameworks for dual-use technologies is exceptionally challenging. The dilemma is to create policies that simultaneously foster innovation, ensure national security, and uphold ethical standards, often under political pressures. Past initiatives, such as the Technology Reinvestment Project (TRP), have struggled to produce technologies that successfully serve both military and commercial needs, often gravitating toward dedicated military production.Lessons from these experiences highlight the need for government agencies to work closely with industry, and for regulations to be agile enough to keep pace with technological advancements, such as the FDA's new regulatory power over cybersecurity standards for medical devices. Future Outlook and Strategic Recommendations The symbiotic relationship between MedTech and defence technology is set to deepen and accelerate. As global security threats evolve and the demand for advanced healthcare solutions grows, the cross-pollination of these two fields will become more deliberate and pronounced. This analysis provides a foundation for navigating this evolving landscape and offers strategic recommendations for key stakeholders. A. Emerging Trends and Trajectories The future of this symbiosis is characterized by three key trends. First, the full integration of AI-powered autonomous systems for medical care is on the horizon, with programs like DARPA's MASH leading the way toward robotic surgical interventions in pre-hospital settings. Second, the "anywhere care" model, which puts the emphasis on delivering health solutions regardless of location, will continue to expand. This includes the use of autonomous medical drones for casualty evacuation and the expansion of telemedicine platforms to provide expert care to remote warfighters and civilians alike. Finally, the use of micro-robotics for invasive, targeted treatments will grow, with potential applications for drug delivery, clearing clogged blood vessels, and precision microsurgery in both military and civilian contexts. B. The Continued Institutionalisation of Symbiosis The trend of government agencies and public-private consortia actively bridging the two sectors will continue to grow. This institutionalization will lead to more deliberate and rapid technology transfer, bypassing the traditionally slow and expensive procurement processes. The models employed by organizations like DIU and MTEC, which prioritize collaboration and the use of flexible funding mechanisms, will serve as a blueprint for future initiatives. This formalisation ensures that innovation is not left to chance but is proactively driven to benefit both national security and global health. C. Strategic Recommendations Based on this analysis, several key strategic recommendations are offered for stakeholders: For Strategic Investors: A focus on companies and technologies with inherent dual-use capabilities—specifically in AI, robotics, advanced materials, and cybersecurity—presents the most fertile ground for cross-sector revenue and robust demand. Investing in companies that demonstrate strong public-private partnership models, or that are actively engaged with organizations like DIU and MTEC, can provide a significant competitive advantage by tapping into both government and commercial markets. For Policymakers: The development of clearer, more nimble regulatory frameworks is essential to account for the dual-use nature of technology. This requires fostering collaboration and communication between medical and defence regulatory bodies to prevent conflicts and ensure that innovations can be scaled and deployed safely and efficiently. Additionally, government programs should learn from the successes and challenges of past initiatives to create funding models that promote the co-development of solutions rather than bifurcating them. For Industry Leaders: Companies should actively embrace collaboration with government R&D agencies and consortia. By prioritizing research and development that addresses core challenges common to both sectors—such as remote care, human performance optimization, and diagnostics in austere environments—companies can create robust, versatile products with built-in demand from both the military and civilian markets. This proactive approach will position them as leaders in the next wave of technological breakthroughs. Nelson Advisors > HealthTech and MedTech M&A Nelson Advisors specialise in mergers and acquisitions, partnerships and investments for MedTech, Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish MedTech and Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views with MedTech and Healthcare Technology insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech founders advising HealthTech and MedTech founders.’ Nelson Advisors partner with entrepreneurs, chair persons, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #MedTech #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT Contact Us lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us at MedTech and HealthTech industry events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Global Health Exhibition 2025 > October 27th-30th 2025, Riyadh, Saudi Arabia Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers and acquisitions, partnerships and investments for MedTech, Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

Digital MSK Europe: Leading HealthTech companies to watch in 2026 Executive Summary: The Dawn of a Data-Driven MSK Revolution The European digital health market is at a pivotal inflection point, with the musculoskeletal (MSK) sector emerging as a primary frontier for innovation and investment. This market is not merely growing; it is undergoing a fundamental transformation, driven by an aging demographic, the increasing prevalence of chronic conditions, and a critical shift towards data-enabled, value-based care. The European Digital MSK market is projected to reach a revenue of US$3.28 Billion by 2030, reflecting a robust Compound Annual Growth Rate (CAGR) of 18.1% from 2025 to 2030. This regional expansion is a significant component of the broader global digital health market, which is advancing at a resilient CAGR of 23.6% for the same period.The immense capital and strategic focus flowing into this sector are creating a new era of competition defined by a strategic clash between well-funded U.S. healthtech titans and clinically-validated European native companies. For a company to emerge as a leader in 2026, its success will depend on more than just technological prowess or financial backing. The ability to navigate the intricate and evolving European regulatory and reimbursement landscape is paramount. The analysis presented herein identifies three core competencies that will serve as predictive factors for market leadership: a proven capacity for securing national reimbursement, particularly through Germany's pioneering Digital Health Applications (DiGA) framework; a foundation of extensive, peer-reviewed clinical evidence that demonstrates both efficacy and cost-effectiveness; and a strategic adaptability that allows for success within Europe's fragmented payer systems, either through a localised, integrated approach or by leveraging global scale to address multi-national clients. The companies poised for success in 2026 are those that have already demonstrated a mastery of these principles, establishing a clear path from innovation to sustainable, scalable market presence. The European Digital MSK Market: Growth Drivers and Strategic Context The digital musculoskeletal health market in Europe is in a phase of dynamic expansion, fueled by strong underlying demand and significant technological advancements. A detailed analysis of the market's quantitative outlook, shifting care models, and strategic benchmarks reveals the key dynamics that will shape the competitive landscape in 2026 and beyond. Market Size, Segmentation, and Forecast for 2026 The market for digital health solutions in musculoskeletal care is growing at a remarkable pace. In 2024, the European market generated a revenue of US1.22billion. Projections indicate a substantial increase, with the market forecast to reach $US3.28 Billion by 2030, representing a healthy CAGR of 18.1% from 2025 to 2030. This growth trajectory underscores the increasing acceptance and adoption of digital solutions by patients, providers, and payers across the continent. An examination of the market's components reveals a significant strategic evolution. In 2024, the "software & services" segment was the largest revenue generator. However, the market highlights identify "hardware" as the most lucrative component, positioned to register the fastest growth during the forecast period. This seemingly paradoxical trend is, in fact, a critical indicator of the market's maturity. The initial wave of digital MSK solutions was predominantly app-based, relying on pure software to deliver care. The next phase of maturity, which will be prominent in 2026, involves more sophisticated, connected hardware such as motion sensors and wearable devices. Companies that can successfully integrate these components will be best positioned to capture this high-growth hardware segment, thereby creating a strategic moat against purely software-based competitors. This also enhances the clinical rigour and data collection capabilities of a solution, which is non-negotiable for securing national reimbursement and demonstrating quantifiable value to payers. From a regional perspective, the market's growth is not uniform. While the United Kingdom, Germany, and France represent major markets, data indicates that Denmark is expected to register the highest CAGR from 2025 to 2030. This suggests a market uniquely receptive to digital health solutions, possibly due to a supportive regulatory environment, high digital adoption rates, or an advanced healthcare system that is already embracing technology-enabled care models. For companies seeking to expand, Denmark may serve as a strategic entry point or a benchmark for success in other countries. Shifting Care Models and Demand Drivers The demand for digital MSK solutions is driven by a confluence of macroeconomic and healthcare-specific trends. Globally, the overarching digital health market is expanding due to a rising geriatric population and the subsequent increase in the prevalence of chronic illnesses. This trend directly applies to MSK conditions, as ailments like back pain and osteoarthritis are chronic and highly prevalent in older populations. In response, healthcare models are rapidly shifting away from purely in-person care towards virtual and hybrid solutions. A survey of U.S. employers provides a glimpse into this future, with 96% of respondents indicating they will offer or are considering offering virtual MSK treatments in 2026/2027. This trend is directly influencing the European market as U.S.-based companies, such as Hinge Health, are launching global solutions to serve their multinational clients. A critical element of this evolution is the ascendance of the hybrid care model. As exemplified by the U.S.-based Limber Health, this model seeks to augment, rather than replace, in-person care with digital tools. By combining in-clinic treatment with digital support for remote therapeutic monitoring (RTM) and home exercise programs, this approach is more palatable and scalable in European healthcare systems, which are often cautious of purely virtual-first models that might bypass traditional providers. It positions digital health companies as strategic partners to existing physical therapists, physicians, and payers, which is a key to gaining widespread adoption and overcoming historical resistance to change. Europe Digital Health for Musculoskeletal Care Market Outlook Data Point Value Context Europe Market Revenue (2024) US$1.224 Billion Historical revenue base for market analysis. Europe Market Forecast (2030) US$3.287 Billion Future projected market size. Europe Market CAGR (2025-2030) 18.1% Annual growth rate. Largest Component (2024) Software & Services Primary revenue driver in recent period. Fastest Growing Component (2025-2030) Hardware Indicative of future market maturation and shift toward connected devices. Key Country for CAGR Denmark Expected to lead regional growth. Navigating the European Healthtech Regulatory & Reimbursement Maze The European market is not a single entity but a collection of diverse national healthcare systems, each with its own regulatory and reimbursement pathways. A company's success in this environment is directly tied to its ability to navigate this complexity. Germany's pioneering DiGA framework provides a strategic blueprint, while broader EU regulations like the EHDS and HTAR are creating a new, data-centric framework for future competition. Germany's DiGA Framework: A Golden Standard for Reimbursement Germany’s DiGA (Digitale Gesundheitsanwendungen) framework is a revolutionary legislative initiative that has officially integrated digital health applications into mainstream medical care. Colloquially known as "apps on prescription," DiGAs can be prescribed by physicians and reimbursed by statutory health insurers, covering approximately 90% of the German population. This framework is the world's first structured pathway for prescribable health apps at scale and provides a powerful precedent for other European countries. A key element of this framework is the "Fast-Track" approval process, managed by the Federal Institute for Drugs and Medical Devices (BfArM). This process allows a manufacturer to receive a provisional listing for a trial phase of up to 12 months, during which the app can be prescribed and reimbursed. This trial period is used to collect the necessary real-world evidence to demonstrate a "positive care effect" for permanent listing. The success of this model is undeniable: the number of approved DiGAs grew from 24 at the end of 2021 to 68 by late 2024, with cumulative reimbursements reaching €234 million. This process is more than a single market entry; it is a critical regulatory "boot camp" that proves a company's product is a true medical device with verified efficacy and security. For other European countries, a DiGA listing serves as a powerful de facto endorsement, making it a crucial strategic milestone. The Broader EU Regulatory Landscape: EHDS and HTAR Beyond Germany, two major regulatory developments are shaping the future of digital health across the European Union. On January 21, 2025, the European Health Data Space Regulation (EHDS) was formally adopted. The EHDS has two primary goals: to improve individuals' access to their electronic health data and to enable the secure, mandatory sharing of this data for secondary purposes, such as research and the training of high-risk AI systems. While the provisions for secondary use will become applicable from 2029, companies holding health data must begin preparing their technical infrastructure and data governance policies now. The EHDS creates a new competitive dynamic where a company's ability to securely manage and leverage this data will become a core business competency. Simultaneously, the Health Technology Assessment Regulation (HTAR), which aims to harmonise the evaluation of new health technologies, will begin its joint clinical assessments in 2026. This regulation will standardize the criteria for evaluating the clinical and cost-effectiveness of new technologies, providing a clear, evidence-based pathway for innovators. The convergence of EHDS and HTAR signals that the future "moat" for digital health companies will be defined not just by technological innovation, but by their capacity to successfully navigate this increasingly harmonised and data-centric regulatory environment. Country-Specific Models: The Fragmented UK Approach In contrast to Germany’s unified framework, the United Kingdom presents a more fragmented reimbursement landscape. There is no single, mandatory pathway for reimbursement, and digital solutions are not widely available on prescription. Instead, adoption and reimbursement decisions are managed locally by regional National Health Service (NHS) bodies known as Integrated Care Systems (ICSs). While the National Institute for Health and Care Excellence (NICE) provides an evidence standards framework to guide the procurement of digital health technologies, this guidance is not directly linked to reimbursement, which can disincentivize robust evidence generation. This fragmented approach requires companies to forge individual contracts and partnerships at the regional level, highlighting a need for a highly localised go-to-market strategy to succeed in the UK. The European Regulatory Landscape for Digital Health Regulation Name Purpose/Key Function Governing Body Scope Effective Date DiGA (Germany) Reimbursement for prescribable digital health apps. Federal Institute for Drugs and Medical Devices (BfArM) Germany-specific In effect since 2019. EHDS (EU) Harmonized framework for primary and secondary use of health data. Health Data Access Bodies (HDABs) EU-wide Adopted 2025; secondary use applicable 2029/2031. HTAR (EU) Harmonized clinical assessment of health technologies. European Commission, Member States EU-wide Joint clinical assessments begin 2026. The Leaders of 2026: Companies to Watch The competitive landscape in 2026 is defined by a strategic contest between a few well-capitalized global players and a select number of clinically-validated European natives. The following analysis profiles the companies best positioned to lead this market. Kaia Health: The Clinically Validated European Native Kaia Health, with its dual headquarters in Munich and New York, stands out as a leading European player with a clear, localised strategy. The company has raised $125 million, a sum that, while significant, is a fraction of the funding secured by its U.S. counterparts. Despite this difference in scale, the company has executed a highly effective strategy centred on clinical rigour and regulatory success. Kaia Health's core technological offering is its AI-powered computer vision, branded as Motion Coach. This proprietary technology provides real-time, physical therapy-grade feedback on exercises using only a smartphone or tablet camera, with no additional sensors or wearables required. This no-hardware approach enhances accessibility and user convenience. The product itself is based on multimodal rehabilitation (MMR), an evidence-based approach that combines guided exercises with relaxation practices and pain education, which is the international gold-standard for chronic pain management. The company's position as a leader is built on a foundation of robust clinical evidence. Kaia Health is described as one of the most clinically validated digital MSK providers. The company conducted the industry's largest randomised controlled trial (Rise-uP), which demonstrated an 80% reduction in costs compared to standard-of-care treatments. A separate study also validated its AI's accuracy, showing it can provide exercise feedback as accurately as a human physical therapist. However, the most critical differentiator for Kaia Health is its proven ability to navigate the European regulatory landscape. The company has secured a DiGA listing in Germany for its chronic back pain app and its COPD app. This achievement is a testament to its commitment to clinical excellence and its strategic focus on securing a direct reimbursement pathway. By obtaining the DiGA "golden seal" of approval, Kaia Health has de-risked its model and established a powerful proof point that will be invaluable for convincing payers and providers in other countries to adopt its solution. The company has stated its intent to use this success to expand its solutions through national reimbursement systems across Europe. The U.S. Titans: Hinge Health & Sword Health While European natives like Kaia Health are carving out a strategic niche, U.S.-based giants Hinge Health and Sword Health are leveraging their global scale and immense funding to penetrate the European market. Hinge Health: With over $854 million in funding, Hinge Health IPO'd in May 2025 and has a valuation of $6.2 billion as of late 2021. The company's European market strategy is centred on its "Global" solution, which offers personalised and accessible care to members outside the U.S. through a single app. This approach primarily targets multinational employers and health plans, aiming to leverage existing relationships to build a presence in Europe. The Hinge Health platform combines expert clinical care with a comprehensive clinical team and utilises both advanced computer vision and wearable sensors. Its clinical evidence includes a peer-reviewed study showing a 73% reduction in acute pain. Sword Health: Founded in Portugal, Sword Health now has a significant presence in the U.S. and Europe, with $450 million in funding and a $3 billion valuation as of late 2021. Sword’s model pairs AI with licensed clinicians and relies on wearable motion sensors. The company boasts an extensive body of clinical research, with over 40 peer-reviewed papers. A key differentiator for Sword is its explicit focus on health equity. Its research demonstrates that its solution delivers high engagement and stellar clinical outcomes in diverse populations, regardless of their location, race, or socioeconomic background. Emerging Local Innovators & Niche Players The European market is not a winner-take-all environment. Smaller, localized innovators demonstrate alternative, successful strategies. A notable example is getUBetter from the UK. The company has developed a self-management app for common MSK conditions that is integrated with and offered by local NHS clinical teams and GPs. This model, which is tailored to specific country-level health systems, proves that success can be achieved by working within the existing healthcare infrastructure rather than attempting a large-scale disruption. Other promising startups, such as Cure Bionics (Tunisia), which focuses on 3D-printed bionic arms, and Horus ML (Spain), which uses AI for cardiovascular risk detection, indicate a rich ecosystem of innovation beyond core MSK pain management. Table 3: Comparative Analysis of Leading Digital MSK Companies Feature Kaia Health Hinge Health Sword Health Total Funding $125 million $854 million $450 million Latest Valuation / IPO Status Undisclosed $6.2B (2021) / IPO May 2025 $3B (2021) Primary Headquarters New York, Munich San Francisco New York, Lisbon Technology AI Computer Vision (No sensors) Computer Vision + Wearables AI + Wearable Sensors European Market Strategy Focus on national reimbursement (DiGA) Global solution for multinational employers International expansion via employer/health plan partnerships Clinical Evidence Highlights Largest RCT (80% cost reduction); AI accuracy on par with PTs Peer-reviewed studies on pain reduction 40+ peer-reviewed papers; focus on health equity European Regulatory Successes DiGA listing for MSK and COPD apps None mentioned MDR CE Mark Future Outlook and Strategic Recommendations for 2026 The analysis of the European digital MSK landscape in 2026 reveals a market on the verge of significant consolidation and strategic realignment. For investors, payers, and industry stakeholders, a nuanced understanding of these dynamics is crucial for making informed decisions. Investment & Partnership Opportunities Companies with a proven track record of navigating European regulatory frameworks represent de-risked investment opportunities. For instance, a company that has successfully secured a DiGA listing in Germany, such as Kaia Health, has demonstrated its ability to achieve a clear, established path to reimbursement. This strategic focus is often a more capital-efficient path to market than a high-spend, global-scale approach. As a result, such companies are likely to attract significant investment and partnership interest. Beyond direct-to-patient solutions, a promising area for investment lies in "enabler" companies that facilitate the hybrid care model. Solutions that provide software for existing providers, as exemplified by the U.S.-based Limber Health, are highly likely to gain traction in Europe. This approach aligns with the cautious nature of many European healthcare systems by working with, rather than against, existing infrastructure. The formal adoption of the EHDS also signals that companies specialising in secure health data management and AI development for clinical applications will be highly valuable acquisition targets, as their expertise will be essential for navigating the complex data-sharing requirements of the future. Key Success Factors for 2026 and Beyond The future leaders of the European digital MSK market will share several key characteristics that go beyond their initial funding or brand recognition. Regulatory First: A company's success in Europe will be determined by its regulatory strategy before its product is even launched. A clear reimbursement pathway is non-negotiable for achieving widespread adoption. The achievement of a CE Mark and, most importantly, a DiGA listing, serves as the ultimate proof of a company's regulatory and clinical maturity. Evidence-Based Value Proposition: The emphasis from payers and health systems will increasingly be on quantifiable outcomes and demonstrable cost savings. The impressive claims of Kaia Health regarding an 80% cost reduction and the focus of Vori Health on impacting key health quality measures like HEDIS are not just marketing points; they are essential components of a successful value proposition. Localisation and Interoperability: A one-size-fits-all approach will fail in a region with such diverse healthcare systems. Leaders in 2026 will have localised content, multilingual support, and the ability to seamlessly integrate with existing EHR systems and care models. The success of a company like getUBetter, which is deeply embedded in local NHS services, demonstrates the power of a localised, interoperable approach. In conclusion, the European digital MSK market in 2026 will be defined by a new level of maturity. Success will not be measured by the size of a company's war chest but by its ability to demonstrate a clear return on investment, backed by robust clinical evidence and a well-defined regulatory and reimbursement strategy. The companies to watch are those that have already begun building these foundational competencies, positioning themselves as indispensable partners to the continent’s healthcare systems. Nelson Advisors > HealthTech and MedTech M&A Nelson Advisors specialise in mergers and acquisitions, partnerships and investments for MedTech, Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish MedTech and Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views with MedTech and Healthcare Technology insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech founders advising HealthTech and MedTech founders.’ Nelson Advisors partner with entrepreneurs, chair persons, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #MedTech #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT Contact Us lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us at MedTech and HealthTech industry events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Global Health Exhibition 2025 > October 27th-30th 2025, Riyadh, Saudi Arabia Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers and acquisitions, partnerships and investments for MedTech, Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

Ambient Voice Technology in the UK > Research Series by Nelson Advisors Ambient Voice Technology in the UK > Research Series by Nelson Advisors 1) NHS England issues guidance on Ambient Voice Technology Ensuring Safe and Assured Adoption of AI Scribes https://www.healthcare.digital/single-post/nhs-england-issues-guidance-on-ambient-voice-technology-ensuring-safe-and-assured-adoption-of-ai-scr NHS England has issued an urgent notification regarding the use of Ambient Voice Technology (AVT) solutions, also known as AI scribe technology, in clinical settings. While acknowledging the transformative potential of AVT for improving patient care and efficiency, the NHS is concerned about the widespread use of non-compliant solutions, posing significant risks to clinical safety and data security. Key Directives for NHS Organisations All NHS organisations, regardless of care setting, are mandated to ensure that any AVT solutions in use meet specified NHS standards. Non compliant solutions, whether procured through free trials or direct commissioning, are not permitted. The liability for using non-compliant solutions rests with the deploying organisation (eg. general practice or trust) or individual user. 2) The Accelerating UK NHS Ambient Voice Technology Market: Dynamics, Key Players, and Strategic Imperatives report by Nelson Advisors https://www.healthcare.digital/single-post/the-accelerating-uk-nhs-ambient-voice-technology-market-dynamics-key-players-and-strategic-impera The UK National Health Service (NHS) is experiencing a rapid acceleration in the adoption of Ambient Voice Technology (AVT), driven by an urgent imperative to alleviate administrative burdens on clinicians and enhance patient care. This report provides a comprehensive analysis of this burgeoning market, detailing the technology's core functionalities, the powerful drivers behind its growth, the strategic positioning of key market players, the intricate regulatory landscape, and the significant challenges that must be navigated for successful, widespread scaling. AVT, characterised as AI-enabled ambient scribing, unobtrusively captures patient-clinician conversations, transforming spoken dialogue into structured medical documentation with minimal user intervention. This evolution from basic dictation tools to intelligent AI assistants represents a profound shift, enabling clinicians to re-focus on patient interaction rather than administrative tasks. The market's expansion is fuelled by a critical need to combat widespread clinician burnout, improve productivity, and align with the NHS's ambitious digital transformation agenda. High-level government endorsement, coupled with substantial investment, underscores AVT's role as a strategic enabler for workforce sustainability and system efficiency. The competitive landscape features a mix of established technology giants and agile innovators, each employing strategic partnerships to navigate the complex NHS ecosystem. Companies like TORTUS AI, Heidi Health, Scribetech, Suki, Nuance, and Tandem are vying for market share, with their success increasingly tied to demonstrable regulatory compliance and clinical safety. However, the path to pervasive adoption is not without hurdles, including the need for a robust evidence base, mitigation of AI bias, seamless integration with legacy IT systems, and fostering trust among both clinicians and patients. Ultimately, the trajectory of AVT in the NHS hinges on a delicate balance between technological innovation, rigorous regulatory adherence, and effective change management. By strategically addressing these multifaceted dimensions, the NHS can unlock the full transformative potential of AVT, leading to improved clinical efficiency, enhanced patient outcomes, and a more sustainable healthcare workforce. 3) Ambient Voice Technology and the NHS 10 Year Plan: Strategy, Future Applications, Key Suppliers, Funding and Regulatory Landscape https://www.healthcare.digital/single-post/ambient-voice-technology-and-the-nhs-10-year-plan-strategy-future-applications-key-suppliers-fun Ambient Voice Technology (AVT), often referred to as Ambient AI or AI scribes, is poised to fundamentally transform the National Health Service (NHS) by streamlining clinical workflows, enhancing productivity, and alleviating the profound administrative burden on healthcare professionals. This technology, which leverages advanced speech recognition and natural language processing, captures patient-clinician conversations in real-time, automatically drafting structured medical notes, letters, and clinical codes. This capability directly aligns with the UK Government's ambitious 10-Year Health Plan for England, published in July 2025, which mandates a shift from an analogue to a digitally-driven, community-focused and preventative care model, explicitly identifying AI scribes as a core enabler of this transformation. Interim trial data, notably from the Great Ormond Street Hospital (GOSH)-led London-wide evaluation, demonstrates significant benefits, including reduced administrative time, increased direct patient care, and enhanced productivity in high-demand settings like A&E. Projections suggest widespread adoption by 2027, with future developments encompassing multilingual capabilities and integration with wearables. The market for AVT in the UK is dynamic, with key players such as TORTUS AI, Heidi Health, Nuance (Microsoft Dragon Copilot), and Tandem actively engaged in NHS trials and deployments. These suppliers are increasingly differentiating themselves through robust compliance with stringent regulatory requirements, including MHRA medical device classification and the NHS Digital Technology Assessment Criteria (DTAC). The government has committed substantial funding, including a record £26 billion for NHS and social care with specific allocations for pioneering technology, and the NHS AI Lab's Artificial Intelligence in Health and Care Award provides phased funding to accelerate promising AI solutions. However, challenges persist, notably fragmented procurement processes and potential funding disparities across trusts, which could impede equitable access and widespread adoption. The regulatory landscape, overseen by the MHRA, is evolving rapidly to ensure AI safety, data protection, and ethical deployment, classifying AVT solutions that perform summarization as medical devices requiring rigorous compliance. The successful integration of AVT hinges on navigating these complexities, ensuring robust data governance, fostering clinician buy-in, and streamlining procurement to unlock its full transformative potential for a more efficient, patient-centred, and sustainable NHS. 4) NHS Ambient Voice Technology Market Heats Up in the UK - key players include TORTUS AI, Heidi Health, ClinicLetter.ai, Scribetech, Suki, Nuance, Tandem https://www.healthcare.digital/single-post/nhs-ambient-voice-technology-market-heats-up-in-the-uk-key-players-include-tortus-ai-heidi-health The NHS ambient voice technology market in the UK is indeed a rapidly evolving and competitive space, driven by the critical need to alleviate administrative burdens on clinicians and improve patient care. Key Players and Their Contributions: TORTUS AI remains a leading player, actively involved in significant NHS trials, notably the London-wide AVT trial led by Great Ormond Street Hospital for Children. Their "Surgery Intellect" solution focuses on generating clinical notes, referral letters, and coding directly from consultations, aiming to reduce administrative time and improve clinician focus on patients. They have demonstrated promising results in reducing admin and are expanding their presence in GP practices, hospitals, and ambulance services. https://tortus.ai Heidi Health is gaining traction with its AI-powered medical scribe, which transcribes patient visits, generates clinical notes, and drafts documents. They emphasize robust UK compliance, local data hosting, and temporary data storage to ensure data security and privacy, which is crucial for NHS adoption. https://www.heidihealth.com/uk ClinicLetter.ai fits directly into the ambient voice technology space, focusing on generating medical letters and documentation from clinician-patient conversations. While specific large-scale NHS trial details might be less publicly prominent than some other players, their core offering directly addresses a key administrative pain point in the NHS. ClinicLetter.ai leverages generative AI to convert spoken words into structured medical documentation. https://www.clinicletter.ai Scribetech continues to be a strong contender with its "Augnito Omni" AI scribe technology and "Augnito Spectra" for speech recognition. Building on their extensive experience in providing transcription services to the NHS, they are well-positioned to integrate advanced AI into existing workflows, aiming for significant reductions in documentation time and seamless Electronic Patient Record (EPR) integration. https://scribetech.co.uk Suki AI offers an AI assistant that provides ambient documentation, dictation, and coding capabilities, along with the ability to answer clinician questions. Their focus on deep integration with major EHRs and minimizing hallucination risks aligns with NHS requirements for reliable and accurate data. Their partnership with Google Cloud indicates a commitment to leveraging advanced AI platforms. https://www.suki.ai/suki-platform/ As part of Microsoft, Nuance is a powerful force in the market. Their "Dragon Medical One" and "Dragon Copilot" solutions utilize advanced speech recognition and AI to enhance productivity, improve the value of clinical data, and streamline workflows for healthcare professionals. Their long-standing presence and integration capabilities are significant advantages. https://www.microsoft.com/en-gb/health-solutions Tandem Health, through its partnership with Accurx (a widely used NHS communications platform), is deploying "Accurx Scribe, powered by Tandem." This collaboration allows them to provide real-time transcription, coding, and document generation to a vast network of NHS professionals, directly addressing the need to reduce admin time and enable clinicians to focus on patient interaction. https://www.tandemhealth.ai 5) Ambient Voice Technology in Healthcare: Predictions for 2026 https://www.healthcare.digital/single-post/ambient-voice-technology-in-healthcare-predictions-for-2026 Ambient Voice Technology (AVT), once considered a speculative innovation, is rapidly evolving into a strategic necessity for healthcare organizations. Fuelled by an urgent need to combat clinician burnout, address rising administrative workloads, and enhance operational efficiency, AVT is poised to fundamentally reshape the clinical workflow. The market is transitioning from an experimental phase to a mature, regulated ecosystem where this technology is no longer a luxury but a foundational layer of modern care delivery. Key predictions for 2026 indicate a period of explosive growth and maturation. The analysis suggests that AVT adoption will reach critical mass, with an estimated 320% increase in implementation plans among healthcare executives. Financially, the technology's value proposition will be irrefutable, proving to be not only a cost-saver by reducing administrative overhead but also a direct driver of new revenue through increased patient throughput and higher coding accuracy. This market expansion, however, will be met with a maturing and increasingly stringent regulatory landscape, exemplified by the UK’s reclassification of AVT as a medical device (SaMD). This will force vendors and health systems to prioritise robust governance and compliance to mitigate clinical and legal risks. Looking beyond mere documentation, the technology will evolve into a proactive clinical partner, integrating with wearables, providing real-time decision support, and orchestrating entire clinical workflows. The ultimate success of this transformation will hinge on addressing critical challenges related to patient trust, algorithmic bias, and seamless interoperability, turning these hurdles into opportunities for competitive differentiation and long-term value creation. Nelson Advisors > HealthTech and MedTech M&A Nelson Advisors specialise in mergers and acquisitions, partnerships and investments for MedTech, Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish MedTech and Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views with MedTech and Healthcare Technology insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech founders advising HealthTech and MedTech founders.’ Nelson Advisors partner with entrepreneurs, chair persons, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #MedTech #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT Contact Us lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us at MedTech and HealthTech industry events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Global Health Exhibition 2025 > October 27th-30th 2025, Riyadh, Saudi Arabia Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers and acquisitions, partnerships and investments for MedTech, Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

Nelson Advisors interviewed by HSJ for their 'The Ambient Voice Technology will hear you now' story HSJ: The Download Nelson Advisors partner Lloyd Price interviewed for HSJ's Download column and Expert Briefing story 'The Ambient Voice Technology will hear you now'. https://www.hsj.co.uk/expert-briefings/the-download-the-avt-will-hear-you-now/7039982.article Across a range of software providers and settings over the past three months, The Download has been aware of: AVT that enters simple mishearing mistakes on to patient records AVT recording a conversation between a clinician and patient that overheard a separate conversation in the background and conflated the two on to one record; and AVT in a mental health trust that wouldn’t take notes on a patient discussing suicide because the software it was adapted from had rules about not encouraging people to harm themselves. One healthtech executive told me that because AVT tech was already so widely in use, especially in primary care, it would take a patient death and a referral to the General Medical Council to get properly enforced, pro-active regulation. So why the big push? Why are trusts everywhere trialling it? Because in the main, it works. Because with some caveats, staff seem to like it. But what do patients think? Lloyd Price, partner at healthtech M&A advisers Nelson Partners, said the London results were encouraging on that front also. He said: “One of the biggest takeaways from the GOSH trial is the high level of public comfort and consent rate to using ambient voice technologies. To generate all of the productivity and efficiency gains, patients/carers/parents need to agree to being recorded and transcribed. Without high levels of public trust, technology solutions will struggle to be adopted and scaled beyond initial pilot sites and departments. “The high consent rates in trials like GOSH demonstrate that patients and parents are willing to embrace technology when they can clearly see the benefit, namely, a better, more focused and more humane clinical experience.” Nelson Advisors > HealthTech and MedTech M&A Nelson Advisors specialise in mergers and acquisitions, partnerships and investments for MedTech, Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish MedTech and Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views with MedTech and Healthcare Technology insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech founders advising HealthTech and MedTech founders.’ Nelson Advisors partner with entrepreneurs, chair persons, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #MedTech #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT Contact Us lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us at MedTech and HealthTech industry events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Global Health Exhibition 2025 > October 27th-30th 2025, Riyadh, Saudi Arabia Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers and acquisitions, partnerships and investments for MedTech, Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

A Strategic Analysis of Top European Business Schools and Their HealthTech Ecosystems Executive Summary The landscape of business education in Europe is undergoing a fundamental transformation, with HealthTech emerging as a critical nexus of innovation, capital, and leadership. This analysis posits that the traditional metrics of institutional prestige, while important, no longer provide a complete picture for prospective students and industry partners. A more granular, and ultimately more valuable, evaluation necessitates an in-depth examination of a school's specific HealthTech ecosystem, which includes not only academic offerings but also student societies, institutional initiatives, and its ability to convene key industry stakeholders. This report reveals a diversified and nuanced landscape. London Business School (LBS) and HEC Paris continue to hold prominent positions in Europe-wide rankings. However, when viewed through a HealthTech lens, other institutions demonstrate a more focused and arguably more impactful commitment. IESE Business School, for instance, exhibits the most robust, institutionally-backed ecosystem, driven by a dedicated Healthcare Initiative and a highly influential annual conference. London Business School's true advantage lies in its "mega-ecosystem," leveraging a vibrant student club and its strategic location near specialised institutions like UCL's Global Business School for Health. Meanwhile, SDA Bocconi and EDHEC Business School stand out for their highly specialised academic programs. SDA Bocconi offers a dedicated Master of International Healthcare Management, Economics and Policy (MIHMEP), while EDHEC provides a highly specialised Executive MBA in Healthcare Innovation & Technology. Conversely, some top-ranked schools like INSEAD and HEC Paris, despite their overall prestige, do not feature a dedicated HealthTech club in the provided materials. Their strength lies in a more integrated approach, where students leverage broader clubs (e.g., Entrepreneurship, Blockchain) and specialised academic programs (e.g., Data Science & AI) to pursue HealthTech interests, offering a more generalist pathway. The strategic conclusion is that the ideal school is highly dependent on a candidate's specific career goals. A professional seeking high-level corporate networking would be well-served by IESE, while an individual aiming for a structured academic pivot might find SDA Bocconi or EDHEC more suitable. For those looking to leverage a vast, urban innovation hub, LBS and its surrounding network offer a compelling proposition. Introduction: The HealthTech Imperative in European Business Education The global healthcare industry is in the midst of a profound and rapid evolution, driven by a confluence of demographic, technological, and economic forces. The rise of digital health solutions, the application of artificial intelligence and machine learning, and the increasing demand for more efficient and accessible care have given birth to the HealthTech sector. This sector is no longer a niche, but a core component of the global economy, attracting immense investment and necessitating a new kind of business leader who is fluent in both management principles and the specific dynamics of healthcare. The purpose of this report is to move beyond conventional business school rankings and provide a granular analysis of the institutional commitments, academic programs, and student societies that constitute a school's true HealthTech ecosystem. By deconstructing the offerings of leading European institutions, this analysis aims to provide a critical guide for future leaders and industry partners. It examines how schools are responding to the HealthTech imperative, whether through dedicated academic tracks, research initiatives, or dynamic student-led communities. The analysis synthesises data from various prestigious rankings, including the Financial Times, Bloomberg, and QS, with detailed information from university-specific materials to provide a holistic and comparative perspective. The Foundation of Prestige and Excellence The initial step in evaluating any business school is to establish its standing within the broader context of European business education. The Financial Times (FT) 2024 European Business School Ranking provides a key baseline, highlighting the dominance of French, British, and Spanish institutions.INSEAD made an extraordinary leap from 18th in 2023 to claim the top spot in 2024, followed by previous leaders HEC Paris and London Business School (LBS). This ranking, the 21st annual edition, is a composite of a school’s performance across multiple program types, including MBA, Executive MBA (EMBA), and Master in Management (MiM), and also considers factors such as faculty diversity and international scope. To provide a more comprehensive view, this analysis also incorporates other prominent rankings. Bloomberg's 2023-24 list places Italian business school SDA Bocconi at the forefront, followed closely by Spain's IESE Business School. Bloomberg's methodology is distinct, weighting indices such as Compensation, Learning, Networking, and Entrepreneurship. Meanwhile, the QS Global MBA Rankings for 2024 recognise London Business School as the top MBA program in Europe and fourth globally. This variety in methodology underscores that no single ranking captures a school's full value, and it sets the stage for a more nuanced examination of their specialized strengths. The following table provides a quick, comparative snapshot of these schools' general prestige across different ranking bodies. School Name FT Rank (2024) Bloomberg Rank (2023-24) QS Global MBA Rank Key Strengths INSEAD 1 4 N/A Extraordinary performance across all programs, particularly EMBA and MiM HEC Paris 2 9 2 Top-tier performance in MBA and MiM programs; strong national and international reputation London Business School 3 5 1 Premier London institution with strong global recognition; top-ranked MBA program in Europe IESE Business School 4 2 N/A Excels in Compensation and Learning; known for diversity and global focus SDA Bocconi 6 1 13 Strong performance in Compensation and Learning; noted for its specialized academic offerings Mannheim Business School N/A 7 N/A Strong German institution with a practitioner-oriented approach and robust networking Deep Dive into Leading HealthTech Ecosystems This section provides a detailed analysis of the institutions that demonstrate the most significant commitment to the HealthTech sector, moving beyond general rankings to a granular, sector-specific evaluation. IESE Business School: The Center for Applied HealthTech Research and Networking IESE Business School in Spain has cultivated what is arguably the most robust and institutionally-backed HealthTech ecosystem in Europe. This is anchored by the formal "IESE Healthcare Initiative," whose mission is to transform the healthcare industry through a tripartite approach: educating leaders, developing applied research, and acting as a forum for all industry stakeholders. The initiative's focus areas are comprehensive, covering the management of health systems, health economics and policy, and the management of pharmaceutical and biotechnology companies. The academic and research foundation is solidified by the "Center for Research in Healthcare Innovation Management (CRHIM)". The center’s research lines directly address modern HealthTech challenges, including "Digital Health Solutions," "Hospital Value Creation," and "Effective Market Access". The research is highly collaborative, with partners spanning public institutions, pharmaceutical giants, and medical device companies. For students, this commitment is most visible through the dedicated "Healthcare Club". Its mission is to increase understanding of the industry and provide career support through training and mentoring. The club's flagship event is the annual "Healthcare Day," a student-run conference that serves as a powerful demonstration of the school's convening power. The speaker lists for these events are not merely a collection of names but a powerful indicator of the school's deep-rooted network within the industry. Speakers include top executives such as the Chairman and CEO of Johnson & Johnson, the Innovation & Digital Strategy Director at AstraZeneca, and partners from Deloitte, as well as leaders from hospitals and startups.The frequent presence of IESE professors, like Professor Núria Mas, alongside these senior-level executives highlights a deep, symbiotic relationship between the school's academic rigour and its practical industry engagement. This established reputation as a hub for industry thought-leadership is a crucial differentiator. London Business School (LBS): The Mega-Ecosystem Advantage London Business School's strength in HealthTech is not self-contained but rather is derived from its position at the heart of London's vast, institutional ecosystem. The school, a premier institution and the top-ranked European MBA program in the QS rankings, provides a strong on-campus foundation with its dedicated "Healthcare Club". The club organises an annual "London Business School Healthcare Conference" and other events, such as a "Fireside chat" with leaders from the Cleveland Clinic, demonstrating an active and engaged student community. The club also collaborates with other student groups, including the Women in Business and Entrepreneurship Clubs, on events with industry leaders like the founder of Praava Health, a rapidly growing healthcare provider in South Asia. The true power of an LBS education in HealthTech extends beyond its own campus. The school is strategically located near two of the world's leading specialized institutions: the UCL Global Business School for Health (UCL GBSH) and Imperial College London's WHO Collaborating Centre. The UCL GBSH is touted as the world's first business school dedicated entirely to health. Its "MBA Health" program offers a specialist, health-focused curriculum designed for ambitious leaders, blending traditional MBA competencies with practical application in healthcare management. Similarly, Imperial College London's "WHO Collaborating Centre" specialises in public health education, technical collaboration, and research in areas such as digital health, health systems resilience, and infectious disease control. The LBS student, therefore, gains access not only to a robust professional network and a dynamic student community but also to the unparalleled academic and research specialisations of these surrounding institutions. SDA Bocconi: The Path of Focused Academic Immersion SDA Bocconi's approach to HealthTech is defined by its deep academic specialization. The school offers a formal and direct pathway into the sector through its Master of International Healthcare Management, Economics and Policy (MIHMEP). This program is a one-year, full-time master's degree aimed at those who aspire to international roles in the healthcare industry, whether in the private sector, government, or healthcare service providers. The curriculum is a major selling point, with a focus on both the "hard skills" and "soft skills" required for leadership in the sector. It includes highly relevant courses such as "Digital Health, Big Data and Data Science," "Quality and Operations Management," and "Insurance Policy and Management". The program is specifically designed to address the unique managerial challenges of a wide array of healthcare organizations, from hospitals to nursing homes and integrated delivery systems. This is complemented by a student association explicitly dedicated to "Data Analytics and Artificial Intelligence in Health Sciences". The SDA Bocconi model is distinct in that its strength is rooted in its highly structured, specialised academic programs and courses. This makes it an ideal choice for candidates seeking a deep-learning experience from the outset, where the student associations complement the academic rigor rather than serving as the primary entry point to the industry. EDHEC Business School: The Entrepreneurial Executive's Choice EDHEC Business School's commitment to HealthTech is highly specialized, targeting a unique demographic of experienced professionals. Its key offering is the part-time "Executive MBA in Healthcare Innovation & Technology" (EMBA HIT). This program's value proposition is its interdisciplinary approach, delivered in partnership with UTC, a "world-class engineering school recognised in biomedical & health research and innovation". The EMBA HIT is designed to equip healthcare managers and professionals with the business acumen, critical thinking, and vision needed to lead in a fast-changing healthcare ecosystem. The curriculum is directly aligned with the sector's needs, featuring specialised modules on "Healthcare Strategy and New Game Changers in Healthcare 2.0," "Leading Health Innovation in the Digital Age," and "Data and Artificial Intelligence in Healthcare". The program has been recognised for its excellence, ranking in the top 30 worldwide for Executive MBA programs and, notably, ranked first globally for participant satisfaction by the Financial Times in 2024. While the provided materials do not indicate a dedicated, general student-led HealthTech club for the broader MBA program, this is not a weakness but a reflection of a distinct strategic model. EDHEC's commitment is through a formal, specialised academic program for a specific, mid-career professional demographic. The lack of a broad student club suggests that the value is derived from a structured, in-depth academic journey rather than from a broad, self-organised student ecosystem. HEC Paris & INSEAD: The Integrated Approach Despite their elite status in general business school rankings, the provided materials do not indicate the presence of a dedicated "Healthcare Club" at either HEC Paris or INSEAD. This might seem like a disadvantage, but it points to an alternative, integrated model for pursuing HealthTech. At HEC Paris, students interested in the sector would leverage broader, professional clubs and specialized academic programs. The school's "Blockchain Club" and general "Entrepreneurship Club" could be used to network and build projects within the HealthTech space. Furthermore, the school's Master of Science in "Data Science & AI for Business" provides a formal academic path to acquire the technical skills necessary for the digital health sector. HEC Paris's overall focus on innovation and entrepreneurship is a key advantage, with the school's startup hub ranking fourth in Europe according to the Financial Times. Similarly, at INSEAD, students would engage with the "Entrepreneurship Club" or "Innovation Club," which are broadly relevant to HealthTech startups and innovative business models. This approach centres on applying general management principles and cutting-edge technologies to any industry, including HealthTech. It is a strategic choice suited for a student who wants to be a versatile leader, able to apply their skills across a range of sectors rather than being siloed in a single industry. Mannheim Business School: A Practitioner’s Focus on Industry Ties Mannheim Business School, a leading German institution, has a solid and practitioner-oriented approach to HealthTech. The school features a dedicated "Healthcare Club," whose mission is to promote education and networking opportunities through collaboration between students, faculty, alumni, and local industry professionals. This club, while not as prominently featured in the provided materials as some of its counterparts, demonstrates a clear focus on the sector. The school's connections to the industry are evident through its guest speakers and academic projects. Mannheim's curriculum, including its strategic projects, has a history of direct corporate engagement, as evidenced by a project focused on developing a "long-term storage solution for medical images". The presence of guest speakers from prominent companies such as Roche Diabetes Care further underscores this focus on direct corporate and practitioner engagement.This combination of a dedicated club and a history of concrete industry projects suggests a strong focus on career placement and professional development within the German and wider European healthcare industry. Comparative Analysis and Nuanced Perspectives The preceding analysis reveals that Europe's top business schools, while all prestigious, approach the HealthTech sector with fundamentally different strategies. There is no single "best" school, but rather a spectrum of models tailored to different professional aspirations. The following table synthesises these findings, providing a direct comparison of each school's HealthTech ecosystem. School Name Dedicated HealthTech Club Type of Commitment Academic Offerings Key Partnerships Ideal Candidate Profile IESE Business School Yes Institutional & Student-Led Healthcare Initiative, CRHIM research center Johnson & Johnson, AstraZeneca, Deloitte, EIT Health Corporate Professional, Aspiring Leader in Pharma/MedTech London Business School Yes Student-Led & Urban Ecosystem MBA Health (via UCL GBSH), WHO Collaborating Centre (via Imperial) UCL, Imperial College London, Cleveland Clinic Career Switcher, Entrepreneur, Networker in the London Tech Cluster SDA Bocconi Yes (AI & Health) Specialized Academic Master in International Healthcare Management, Economics and Policy (MIHMEP) Public/Private healthcare organizations, pharma companies Academic Deep-Diver, Specialist in HealthTech Consulting EDHEC Business School No (Based on materials) Specialized Academic Executive MBA in Healthcare Innovation & Technology UTC (engineering school) Experienced Executive, Mid-Career Professional, Entrepreneur HEC Paris No Integrated Generalist MSc Data Science & AI for Business, Entrepreneurship & Innovation Institute N/A (Generalist focus) Generalist Leader, Technology Strategist, Entrepreneur INSEAD No Integrated Generalist N/A (Generalist focus) N/A (Generalist focus) Versatile Generalist, Entrepreneur, Global Corporate Leader Mannheim Business School Yes Student-Led & Practitioner-Oriented EMBA Strategic Projects in Health Roche, BASF Management Consulting Practitioner, Corporate Manager, Focus on German Market Strategic Recommendations and a Concluding Perspective Choosing the optimal business school for a career in HealthTech requires a sophisticated understanding of a candidate’s specific professional goals and a school’s unique ecosystem. The conventional focus on overall rankings provides only a partial view; the true value is found in the depth and nature of a school's specialised offerings. For the Aspiring Entrepreneur or Technology Strategist: A school with an integrated generalist approach, such as HEC Paris or INSEAD, could be ideal. Their broad curricula and prominent clubs in entrepreneurship and innovation allow for the application of general management skills to a specific industry. An individual at these schools can build a versatile skill set, leveraging core tech and business competencies to navigate the unpredictable and rapidly evolving HealthTech startup world. EDHEC's EMBA HIT offers a more structured version of this path for experienced professionals, with its unique partnership with an engineering school providing an invaluable technical foundation. For the Corporate Professional Seeking a Pivot or Advancement: IESE Business School presents a compelling option. Its institutional commitment and proven ability to convene senior-level leaders from global corporations like Johnson & Johnson and AstraZeneca create an unparalleled networking environment. For an individual looking to transition from a different sector or climb the corporate ladder within a major healthcare company, IESE's established thought-leadership platform offers direct access to key decision-makers. For the Career-Switcher or Academic Specialist: SDA Bocconi's MIHMEP program is a direct and efficient path for those committed to a deep-dive into the healthcare industry. Its curriculum is explicitly tailored to the sector, ensuring that graduates are well-versed in the unique challenges of healthcare management, from operations to digital health. Similarly, an LBS student can strategically tap into the vast ecosystem of London, gaining academic exposure to institutions like UCL's Global Business School for Health, which offers a specialist health-focused MBA, providing a focused academic complement to LBS's general management curriculum. In conclusion, the most successful leaders in the HealthTech sector will not simply graduate from a top-ranked school, but will strategically align their ambitions with an institution whose ecosystem is uniquely suited to their professional journey. The value of a business school in the modern HealthTech landscape is defined not just by its name, but by the tangible, specialized environment it cultivates for its students to innovate, lead, and thrive. Nelson Advisors > HealthTech and MedTech M&A Nelson Advisors specialise in mergers and acquisitions, partnerships and investments for MedTech, Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish MedTech and Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views with MedTech and Healthcare Technology insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech founders advising HealthTech and MedTech founders.’ Nelson Advisors partner with entrepreneurs, chair persons, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #MedTech #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT Contact Us lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us at MedTech and HealthTech industry events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Global Health Exhibition 2025 > October 27th-30th 2025, Riyadh, Saudi Arabia Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers and acquisitions, partnerships and investments for MedTech, Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

The Future of GLP-1 Pills: Paradigm Shift in Obesity Management Executive Summary The landscape of obesity and cardiometabolic disease management is on the cusp of a profound transformation, driven by the emergence of a new generation of oral therapies. For years, the remarkable efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists for weight loss and glycemic control has been inextricably linked to injectable formulations, creating a market dominated by medications like semaglutide (Wegovy) and tirzepatide (Zepbound). However, the imminent approval of highly efficacious oral pills promises to democratise access, disrupt established supply chains, and trigger cascading effects across the entire healthcare ecosystem and beyond. This report provides a comprehensive, multi-faceted analysis of the clinical, economic, and societal forces shaping this future. Key Findings and Strategic Implications The analysis reveals that the next wave of oral GLP-1s, exemplified by Eli Lilly's orforglipron and Novo Nordisk's high-dose oral semaglutide, is poised to rival the efficacy of their injectable counterparts. Clinical trial data demonstrates that these investigational pills can achieve average weight loss percentages and cardiometabolic benefits consistent with established injectable therapies. This breakthrough is significant because it directly addresses several critical barriers to widespread adoption: the aversion to needles, the complex logistics of cold-chain distribution, and the limitations of a global supply chain designed for injectable pens. The GLP-1 market is projected to expand dramatically, with global sales potentially reaching over $139 billion by 2030. The introduction of more accessible and scalable oral options could serve as a primary catalyst for this growth. However, this trajectory is not without complexity. The report identifies that the financial burden remains a central dilemma for payers and employers, who must reconcile the immense short-term budget impact of widespread coverage with the substantial long-term health cost savings from preventing obesity-related comorbidities. Furthermore, the rise of oral pills, while promising, introduces new challenges related to patient adherence and necessitates a shift in patient support strategies to manage daily dosing and common gastrointestinal side effects. Finally, the report finds that the influence of these drugs extends far beyond the pharmaceutical sector. The pill’s widespread availability is poised to reframe obesity from a personal failing to a chronic, treatable disease, potentially reducing societal stigma. Simultaneously, it is already beginning to alter consumer behavior and disrupt the food and beverage industry, which is adapting to a new consumer preference for smaller portions and nutrient-dense foods. The future of GLP-1 pills is not merely a story of new drugs; it is a story of a transformative medical innovation that will redefine the treatment of chronic disease and reshape fundamental aspects of public health and economic activity. The Current Landscape: From Peptide Injections to a Single Pill Incretin Hormones and the Mechanism of Action To comprehend the transformative potential of GLP-1 pills, it is essential to first understand the foundational biology behind this drug class. The human body naturally produces hormones known as incretins, with glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) being the most prominent. These hormones are secreted from the gut in response to food intake and play a crucial role in regulating appetite, blood sugar, and fat storage. The physiological effects are multifaceted and synergistic. GLP-1, for instance, stimulates insulin production from the pancreas in a glucose-dependent manner, meaning it only enhances insulin secretion when blood sugar levels are high. Concurrently, it reduces the release of glucagon from the liver, which prevents the liver from producing excess sugar. Beyond their primary role in glycemic control, GLP-1s also exert a powerful effect on the central nervous system and the gastrointestinal tract. They slow gastric emptying, which delays food absorption and helps individuals feel fuller for longer after a meal. This mechanism, coupled with the activation of GLP-1 receptors in the hypothalamus, helps to suppress sensations of hunger, alleviate food cravings, and enhance feelings of satiety. The cumulative effect of these actions—on insulin, glucagon, gastric emptying, and appetite—is what drives the significant weight loss observed with these medications. However, the native GLP-1 hormone has a very short half-life, being rapidly metabolized by the enzyme dipeptidyl peptidase 4 (DPP-4) within minutes. This inherent instability explains why the first generations of GLP-1 receptor agonists were predominantly administered as subcutaneous injections. The molecular size and structure of these peptide-based drugs made it challenging for them to be absorbed intact through the gastrointestinal tract, leading to a long-standing reliance on injectables to ensure systemic delivery and a prolonged therapeutic effect. The Injectable Dominance: Approved Therapies for Weight Loss The current market for GLP-1 weight loss medications is defined by its injectable form factors. Three drugs are currently FDA-approved for weight management: liraglutide (Saxenda), semaglutide (Wegovy) and the dual GLP-1/GIP receptor agonist tirzepatide (Zepbound). Each of these has established a benchmark for clinical efficacy. Liraglutide, for instance, has been associated with an average weight loss of approximately 8%. Semaglutide, a long-acting GLP-1 receptor agonist administered once a week, has been shown to produce up to a 14.9% average weight loss. However, the current leader in efficacy is tirzepatide, which acts on both GLP-1 and GIP receptors. This dual-agonist mechanism has yielded the most significant weight loss results to date, with clinical trials demonstrating an average weight reduction of up to 22.5%. These established efficacy profiles set a high bar for any new oral therapy seeking to enter the market. The First Oral GLP-1: Rybelsus and its Role While the injectable forms dominate the weight loss landscape, Rybelsus (oral semaglutide) holds the unique distinction of being the first and, for a time, only oral GLP-1 drug on the market. Rybelsus is a daily oral tablet, but its FDA approval is strictly limited to the treatment of Type 2 diabetes to help control blood sugar levels, not for weight loss. Despite this, its ability to promote weight loss as a side effect has led to widespread off-label prescribing for that indication. The development of Rybelsus was a significant scientific achievement, but its formulation inherited the inherent challenges of delivering a peptide orally. To be effective, it must be taken on an empty stomach with a small amount of water at least 30 minutes before the first meal, drink, or other medication of the day to ensure adequate absorption. Due to its lower bioavailability, which is approximately 1% compared to its injectable counterparts, a higher daily dose of 7 mg or 14 mg is required to achieve a therapeutic effect similar to the weekly injectable dose of 1 mg to 2 m. This daily dosing schedule and the complex administration rules have made long-term patient adherence a significant challenge. The Rybelsus experience, while pioneering, underscored that a truly transformative oral GLP-1 for weight loss would need to overcome not just the needle barrier but also the complex dosing protocols that undermine patient convenience and adherence. This created a clear market opportunity for a new generation of oral pills that could offer the simplicity of a daily tablet without the burdensome restrictions of a peptide-based formulation. The New Wave: Oral Therapies in the Pipeline Eli Lilly's Orforglipron: The Non-Peptide Game-Changer Eli Lilly's orforglipron represents a new frontier in the development of oral GLP-1 therapies. It is an investigational, once-daily, small molecule, non-peptide oral GLP-1 receptor agonist. Its designation as a "small molecule" is a critical distinction, as it allows for a different approach to oral bioavailability, a key challenge for peptide-based drugs like Rybelsus. A core advantage of orforglipron is its convenience; unlike Rybelsus, it can be taken at any time of the day "without food and water restrictions". The efficacy of orforglipron has been demonstrated across multiple Phase 3 clinical trials, with data from the ATTAIN and ACHIEVE programs showing results that are consistent with injectable GLP-1 medicines. In the ATTAIN-1 trial, which evaluated the drug in adults with obesity, the highest dose (36 mg) led to a significant average weight loss of 12.4% (27.3 lbs) over 72 weeks. A related trial, ATTAIN-2, which studied a population with obesity and Type 2 diabetes, demonstrated a 10.5% (22.9 lbs) average weight loss on the highest dose over the same period, along with a meaningful A1C reduction of 1.8%. Furthermore, a diabetes-focused trial, ACHIEVE-1, showed that the drug produced a 7.6% weight reduction and a 1.6% A1C reduction at 40 weeks. Across all these studies, the overall safety and tolerability profile of orforglipron was found to be consistent with the established GLP-1 class, with the most common side effects being gastrointestinal-related and generally mild to moderate in severity. Given these compelling results, Eli Lilly has announced plans to submit orforglipron for regulatory review for obesity in 2025, with a submission for Type 2 diabetes anticipated in 2026. This strategic move positions orforglipron as a direct oral competitor to Novo Nordisk's injectable Wegovy and Zepbound, and also as a potential replacement for the less convenient Rybelsus. Novo Nordisk's High-Dose Oral Semaglutide In a parallel effort to maintain its market leadership, Novo Nordisk is also developing a high-dose (50 mg) oral semaglutide specifically for weight management, a substantial increase from the 14 mg maximum dose of Rybelsus. The OASIS 1 Phase 3 trial, a 68-week study, demonstrated the efficacy of this new formulation. Results showed that patients taking the 50 mg dose achieved a clinically meaningful weight loss of 15.1%, compared to a 2.4% reduction with placebo. This result is highly competitive and effectively places the efficacy of this pill on par with its injectable counterpart, Wegovy, which has an average weight loss of up to 14.9%. Novo Nordisk submitted this investigational obesity pill for FDA approval in April 2025, ahead of Lilly' planned submission for orforglipron for obesity. The Small Molecule Advantage and The Next Frontier The development of small molecule oral GLP-1s like orforglipron marks a significant strategic shift in the competitive landscape. The small-molecule nature of orforglipron enables it to be more readily manufactured at a large scale, potentially alleviating the supply chain bottlenecks and shortages that have plagued the injectable GLP-1 market. This scalability offers the potential to launch the drug globally without the supply constraints that have limited access to injectables. The convenience of a once-daily pill without food and water restrictions directly targets the primary reasons for patient reluctance with both Rybelsus and the injectable pen. The competitive calculus is no longer simply about which drug is the most effective; it is about which drug can deliver a comparable level of efficacy with the most convenience and accessibility. This strategic evolution is further complicated by the emergence of next-generation therapies with even greater potential. Eli Lilly's retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon receptors, has shown even higher efficacy in early trials, with weight loss of up to 24.2% at 48 weeks. Similarly, Amgen's MariTide is a monoclonal antibody with the potential for once-monthly dosing, and its Phase 2 trials demonstrated up to 20% weight loss. These developments raise the bar for what is considered a landmark result and suggest that the long-term competition will be fought on multiple fronts, efficacy, delivery mechanism, and dosing frequency, with the pill serving as a foundational and highly strategic entry point for mass market penetration. Clinical Efficacy and Patient Experience: A Comparative Analysis Head-to-Head: Oral vs. Injectable Efficacy The advent of highly effective oral GLP-1s presents a compelling alternative to established injectable therapies. A direct comparison of the clinical data reveals that the new oral formulations are poised to deliver a level of efficacy that is consistent with or comparable to their injectable counterparts, effectively closing a long-standing gap in the market. For instance, the OASIS 1 Phase 3 trial showed that Novo Nordisk's investigational 50 mg oral semaglutide led to a 15.1% weight loss, a result that rivals the 14.9% average weight loss seen with injectable Wegovy. Similarly, Eli Lilly's orforglipron, a non-peptide oral agonist, demonstrated an average weight loss of 12.4% in the ATTAIN-1 trial, a result considered clinically meaningful by experts. While Rybelsus, the first-generation oral semaglutide, has a lower therapeutic dose and is not indicated for weight loss, a clinical study found that it produced weight loss of 5.9 kg at 6 months, a result not statistically different from the 6.5 kg loss seen with injectable semaglutide in a real-world setting. Furthermore, the efficacy of oral formulations extends to cardiometabolic benefits. Oral semaglutide has been shown to be "nearly equally effective" in achieving and maintaining glycemic targets for Type 2 diabetes as its injectable version. A landmark study demonstrated that oral semaglutide reduced the risk of cardiovascular death, heart attack, or stroke by 14% over four years, a result in line with the outcomes of injectable GLP-1 trials. In addition, orforglipron has also shown clinically meaningful benefits on cardiovascular risk factors such as non-HDL cholesterol, triglycerides, and systolic blood pressure. The following table provides a comprehensive overview of the comparative efficacy data for key oral and injectable GLP-1 and multi-agonist therapies: Drug (Brand/Active Ingredient) Formulation Frequency Average Weight Loss (%) Average Weight Loss (lbs) HbA1c Reduction (%) Source/Trial Name Rybelsus (Oral Semaglutide) Oral tablet Daily 5.9 kg (~13 lbs) - -1.4% Real-world study Ozempic (Inj. Semaglutide) Injectable Weekly 3 kg (~6.6 lbs) - - Meta-analysis Wegovy (Inj. Semaglutide) Injectable Weekly 14.9% - - Clinical data Orforglipron (Investigational) Oral pill Daily 12.4% 27.3 lbs - ATTAIN-1 Orforglipron (Investigational) Oral pill Daily 10.5% 22.9 lbs -1.8% ATTAIN-2 Oral Semaglutide 50mg (Investigational) Oral tablet Daily 15.1% - - OASIS 1 Zepbound (Inj. Tirzepatide) Injectable Weekly 22.5% - - Clinical data Saxenda (Inj. Liraglutide) Injectable Daily ~8% - - Clinical data Side Effects and Tolerability A primary consideration for patient experience and long-term adherence is the side effect profile of these medications. The clinical data indicates that the most common adverse events are remarkably consistent across both oral and injectable GLP-1 formulations: they are predominantly gastrointestinal symptoms, including nausea, vomiting, diarrhoea and constipation. In clinical trials for injectable Wegovy, 44% of patients reported nausea, a rate that is notably high. Similarly, Phase 3 trials for orforglipron showed that nausea was the most common adverse event, with reported rates as high as 36.4% in one trial. Other common side effects include abdominal pain, headaches, and fatigue. While serious but rare side effects such as pancreatitis, gallbladder disorders, and acute kidney injury can occur, the vast majority of patients experience mild to moderate GI symptoms that tend to diminish over time as the body adjusts to the medication. The Economic and Market Impact of Oral Formulations Market Size and Growth Forecasts The GLP-1 drug class has already achieved blockbuster status, and forecasts suggest its growth will be nothing short of explosive. The market was valued at $53.46 Billion in 2024 and is projected to reach $156.71 Billion by 2030, representing a compound annual growth rate (CAGR) of 17.46%. Another analysis projects global sales to reach as high as $139 Billion by 2030, a significant increase from an earlier forecast. These figures underscore the immense commercial potential of this drug class, which is being driven by unprecedented efficacy in weight reduction, glycemic control, and a broadening range of indications. The market is currently dominated by a duopoly of Novo Nordisk and Eli Lilly, with the latter recently surpassing Novo Nordisk to capture an estimated 57% of the market in the second quarter of 2025. The introduction of oral options is seen as a "game-changer" for market expansion, with the potential to attract a new patient population that has been reluctant to use injectables. Oral pills are also generally cheaper to produce, which could facilitate broader global access and further accelerate market penetration. The competitive environment is intensifying, with over 60 companies and 65+ GLP-1 agonists in various stages of development, all vying for a share of this rapidly expanding market. The Cost Conundrum: Payers, Employers, and Patients Despite the immense demand and clinical value, the high cost of GLP-1 drugs remains a central barrier to access. List prices can exceed $1,000 a month, placing a significant financial burden on patients without insurance. While manufacturers offer savings programs and some patients with private or employer-covered insurance may pay as little as $10, the majority of people do not pay the full list price, but still face substantial out-of-pocket costs. Over half of adults taking these drugs reported having difficulty paying for them, even when they had some form of coverage. This financial challenge is even more pronounced for payers and employers who bear the primary cost of coverage. A central dilemma exists between the significant upfront costs and the uncertain, long-term health benefits. The analysis shows that while GLP-1s can deliver impressive long-term health improvements and prevent thousands of cases of diabetes and cardiovascular disease, their current prices far exceed standard benchmarks for cost-effectiveness. For instance, one study found that tirzepatide would require a 30% price reduction to meet cost-effectiveness thresholds, while semaglutide would need to cost 80% less. The short-term budget impact is immense, with one state projecting to spend $1.3 Billion on GLP-1 drugs in a single year. The Compounder Problem and Regulatory Hurdles The high cost and persistent supply shortages of FDA-approved GLP-1s have created a robust black market for compounded and unapproved versions of these medications. The FDA has issued strong warnings against these unapproved versions, citing a lack of review for safety and efficacy. The agency has received hundreds of adverse event reports associated with compounded semaglutide and tirzepatide, including instances requiring hospitalisation. These unapproved products may be counterfeit, contain incorrect or harmful ingredients, or lack the proper dosage, posing a serious health risk to consumers. The widespread availability of a highly efficacious, scalable, and potentially lower-cost oral pill serves a strategic purpose beyond simply expanding the market. By providing a convenient and more accessible alternative, the pill could effectively marginalise the black market for compounded and unapproved drugs. This would allow pharmaceutical companies to regain control of the supply chain, re-establish safety and quality standards, and provide a legitimate, regulated alternative for a patient population that is otherwise forced to seek out risky, unapproved products. The pill, therefore, is not just a commercial product but a strategic asset in the broader effort to ensure patient safety and maintain regulatory control of a transformative drug class. Broader Societal and Public Health Implications Reframing Obesity as a Chronic Disease The widespread adoption of GLP-1s, particularly in a convenient pill form, has the potential to fundamentally reframe the public perception of obesity. For decades, obesity has been widely viewed as a matter of personal responsibility or a moral failing, driven by a lack of willpower to eat less and exercise more. This narrative has contributed to significant external and internalised stigma, leading to discrimination in employment, education, and healthcare. However, the medical community increasingly recognises obesity as a complex, chronic disease with multiple neuroendocrine pathways and hormonal imbalances that affect hunger, satiety, and metabolism. The efficacy of GLP-1s in quieting the "food noise", the intrusive, anxiety-provoking thoughts about food that many patients experience, provides powerful physiological evidence that obesity is not simply a behavioural issue. The availability of a simple, effective oral pill validates the medical community's view that obesity is a chronic condition that requires long-term, pharmacological management, much like hypertension or hyperlipidemia. This medical validation can help reduce the stigma that has long been a barrier to seeking and receiving care, empowering patients to view their condition as a treatable disease rather than a personal failure. Ripple Effects on the Food and Beverage Industry The dramatic reduction in appetite and food intake among GLP-1 users is already sending ripple effects through the food and beverage industry. Early evidence suggests that consumers on these medications spend significantly less money on groceries and shift their purchasing habits away from snacks, alcohol, and carbohydrates. This change in consumer behaviour is not just a passing trend; it reflects a fundamental change in the body's neuroendocrine signalling and a shift in food preferences. The industry has begun to take notice. Some restaurants are reviewing their menus and portion sizes, while brands are developing new products or adding "GLP-1 friendly" labels that highlight attributes such as high protein and fibre. The long-term impact on agriculture is also being considered, with some experts suggesting that slowing food demand may require a greater focus on nutritionally dense foods rather than simply production volume. The introduction of widely accessible oral pills could accelerate this transformation, compelling the industry to pivot its strategies to align with the evolving dietary needs and preferences of a large and growing segment of the population. Beyond Weight Loss: Ancillary Health Benefits While the spotlight on GLP-1s has largely been on their weight loss capabilities, their proven benefits extend far beyond cosmetic changes. A growing body of evidence demonstrates their protective effects against a wide range of chronic diseases. GLP-1s have been shown to significantly reduce cardiovascular events and mortality, with a meta-analysis from 2024 confirming that the odds of major adverse cardiac events and all-cause mortality were reduced in patients on these drugs. Notably, the SOUL trial demonstrated that oral semaglutide reduced the composite risk of cardiovascular death, heart attack, or stroke by 14% over a four-year period, proving that the benefits of the class are not exclusive to injectables. Furthermore, GLP-1s are demonstrating a broader therapeutic potential. The FDA has already approved the use of semaglutide for chronic kidney disease in adults with Type 2 diabetes and Zepbound for moderate to severe obstructive sleep apnea in adults with obesity. These drugs have also shown benefits in improving kidney function and treating conditions like metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NAFLD. Researchers are also exploring their potential applications in neurodegenerative diseases like Alzheimer's and Parkinson's, and even for addiction management, which could further broaden their utility and drive demand. These ancillary benefits reshape the framework for how these drugs are evaluated. Rather than being seen as a luxury or a cosmetic intervention, their ability to prevent and manage costly comorbidities positions them as a strategic investment in long-term public health. For payers and employers, this shifts the conversation from a question of how to afford the high short-term budget impact to a recognition that these drugs can generate significant long-term savings by reducing the incidence of expensive, obesity-related health conditions. The pill's potential for lower cost and wider access could accelerate this shift in perspective, making the economic case for broad coverage even more compelling. Future Outlook and Recommendations Key Drivers for Future Growth The future of GLP-1 pills for weight loss is poised for exponential growth, driven by a confluence of powerful factors. The most significant of these is the convenience of oral administration, which directly addresses the major psychological barrier of needle aversion that has prevented millions of patients from accessing these life-changing therapies. The next-generation pills, like orforglipron, further enhance this convenience by removing the complex food and water restrictions associated with first-generation oral therapies. Secondly, the potential for lower manufacturing costs and increased scalability of small-molecule oral pills stands to resolve the persistent supply chain issues that have plagued the GLP-1 market. This scalability could enable a much broader and more rapid global launch, ensuring that demand can be met. Third, the proven efficacy of oral pills on par with their injectable counterparts removes any potential trade-off between convenience and clinical outcome. Patients will soon have a choice between a daily pill and a weekly injection without compromising on weight loss or cardiometabolic benefits. Finally, the expanding indications for these drugs beyond diabetes and obesity into areas like heart failure, MASH, and even neurodegenerative disorders will increase their addressable patient population and further entrench their role as a cornerstone of chronic disease management. Remaining Challenges and Unanswered Questions Despite the promising outlook, several challenges and unresolved questions remain. The long-term safety profile of these medications is still being studied, particularly regarding their effects on the pancreas and other organs. While short-term data is reassuring, the implications of decades-long use are not yet fully understood. Additionally, whether the real-world adherence for a daily pill will be superior to a weekly injection remains an open question. The high rates of gastrointestinal side effects could still pose a significant challenge to long-term compliance, regardless of the administration route. Perhaps the most significant challenge is the development of sustainable coverage models. Given the high cost and the medical consensus that these drugs must be used indefinitely to maintain their benefits, payers and employers face a central conundrum. How can they create economically viable, long-term coverage plans for a drug that millions may need for life? This is a question that will require innovative solutions and a re-evaluation of traditional drug coverage strategies. Recommendations Based on this analysis, the following recommendations are offered for key stakeholders in the healthcare ecosystem: For Pharmaceutical Companies: The primary focus should be on demonstrating the long-term health-economic value of oral therapies to secure favorable and comprehensive coverage from payers. This requires shifting the narrative from a short-term budget impact to a long-term investment that prevents costly comorbidities. Companies should also invest in patient support programs that are specifically tailored to the nuances of oral medication, focusing on managing gastrointestinal side effects and reinforcing the importance of long-term adherence. For Healthcare Providers: The widespread availability of oral GLP-1s provides an opportunity to expand access to a wider range of patients. Providers should embrace a holistic approach, combining medication with essential lifestyle interventions like a balanced diet and regular exercise to maximise weight loss, preserve muscle mass, and improve overall health. Patient education is paramount, ensuring that individuals understand the potential side effects and the need for long-term use to maintain benefits. For Payers and Employers: It is recommended to shift the framework from a short-term budget constraint to a long-term investment in employee and member health. The use of strategic medical management tools, such as prior authorisation and step therapy, can ensure responsible prescribing and help guide patients toward effective, long-term solutions while controlling costs. Investing in complementary programs that support lifestyle changes can also help improve health outcomes and potentially mitigate some of the long-term cost burden. Nelson Advisors > HealthTech and MedTech M&A Nelson Advisors specialise in mergers and acquisitions, partnerships and investments for MedTech, Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish MedTech and Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views with MedTech and Healthcare Technology insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech founders advising HealthTech and MedTech founders.’ Nelson Advisors partner with entrepreneurs, chair persons, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #MedTech #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT Contact Us lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us at MedTech and HealthTech industry events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Global Health Exhibition 2025 > October 27th-30th 2025, Riyadh, Saudi Arabia Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers and acquisitions, partnerships and investments for MedTech, Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

Nelson Advisors: Boutique European MedTech Investment Banking specialising in M&A Advisory Nelson Advisors: Boutique European MedTech Investment Banking specialising in M&A Advisory This report provides a detailed analysis of Nelson Advisors, a highly specialised mergers and acquisitions (M&A), partnerships and investment advisory firm. The firm is exclusively dedicated to the dynamic European medical technology (MedTech) sector, with an extended reach into the UK and North America. The analysis reveals that the firm's primary competitive advantage is rooted in its unique "Founders for Founders" approach, which is underpinned by the direct entrepreneurial experience of its leadership. This model enables a nuanced understanding of the MedTech ecosystem that distinguishes Nelson Advisors from larger, generalist investment banks and M&A advisory firms. The firm's value proposition is built on a dual foundation: the deep, hands-on entrepreneurial background of its founding partner Lloyd Price and the extensive, multi-billion-dollar global M&A expertise of co-founder Paul Hemings. This combination allows Nelson Advisors to provide a sophisticated yet deeply empathetic advisory service. The firm is strategically positioned at the forefront of critical, high-growth sub-sectors such as Healthcare AI and Cybersecurity, and it is particularly focused on guiding early-stage companies through M&A exits. This focus is a direct and intelligent response to current market conditions, including a tighter venture capital funding environment and a less active initial public offering (IPO) market. Overall, Nelson Advisors’ leadership position is not derived from M&A volume or value across all sectors, but rather from its deep, qualitative specialisation and its thought leadership in its dedicated niche. Defining Nelson Advisors: The European MedTech Specialist Nelson Advisors is a highly specialised advisory firm with a singular focus on the healthcare technology sector. It is precisely defined as a mergers and acquisitions, partnerships and investment advisory firm that operates within the dynamic and rapidly evolving HealthTech landscape. This exclusive dedication to a specific industry is the bedrock of the firm's value proposition, providing a nuanced understanding of the unique market dynamics and technological advancements that are essential for successful transactions in this complex field. The firm's primary physical presence is in London, UK, positioning it strategically within the European HealthTech hub. While its physical headquarters are in Europe, its geographic scope is deliberately broad, catering to a client base that spans the UK, Europe, and North America. The international capabilities of its partners are extensive, with corporate finance experience and transaction exposure across numerous countries, including the US, Ireland, Sweden, Denmark, Switzerland, Germany, Austria, Italy, Poland, Ukraine, Russia, Kazakhstan, Hong Kong, Singapore, and Australia. This international reach allows the firm to facilitate complex, cross-border transactions that are increasingly common in the global HealthTech market. Exclusive Specialisation in the MedTech Ecosystem The core of Nelson Advisors' business model is its deep and exclusive specialisation in the HealthTech sector. This focus is a significant competitive advantage over generalist firms, enabling the firm to develop a sophisticated understanding of the industry's complex dynamics. The firm’s expertise extends across a diverse range of sub-sectors, which demonstrates a comprehensive grasp of the entire HealthTech ecosystem. The firm’s specialised sub-segments include: MedTech: Encompasses the use of technology, products, services and solutions to diagnose, prevent, monitor, treat, and alleviate diseases and health conditions. It is a critical component of modern healthcare, enabling medical professionals to provide more accurate, efficient, and effective care. HealthTech: The firm’s focus here is on fundamental technological innovations in healthcare, such as advanced medical devices, robotics, bioprinting, and nanotechnology. These are often associated with early-stage companies and startups developing novel solutions to healthcare challenges. Digital Health: This area covers a broad range of technology-driven solutions, including mobile health apps, telehealth platforms, wearable devices, and personalized wellness solutions. Health IT: This specialisation centres on the technology used to manage, store, and share health information, including systems like electronic health records (EHRs) and clinical decision support tools. Consumer Health: The firm advises companies that provide solutions directly to the end user, including AI-driven diagnostics and digital biomarkers. Healthcare Cybersecurity: This is a crucial area of specialisation dedicated to ensuring the confidentiality, integrity, and availability of sensitive healthcare information and systems. The firm's focus on this segment is a direct response to the sensitive nature of patient data and the increasing sophistication of cyber threats. Healthcare AI: This sub-sector leverages AI techniques like machine learning and natural language processing to analyse complex medical data, provide insights, and enhance operational efficiency. The firm's explicit inclusion of Healthcare AI and Cybersecurity is not just a listing of services but a strategic signal of long-term foresight. The partners understand that these specific, complex, and high-growth areas will be central to future value creation and risk management in HealthTech. The firm's proactive specialisation in these sub-sectors, which are subject to emerging regulations like the EU AI Act and the European Health Data Space (EHDS), distinguishes them from firms with a more general HealthTech focus. This expertise is invaluable for clients who need to navigate advanced technological landscapes and stringent regulatory environments. Comprehensive M&A and Advisory Services Nelson Advisors offers a comprehensive suite of advisory services that are meticulously tailored to address the diverse needs of its clients. The firm provides a full range of M&A services, including both buy-side and sell-side advisory. For companies seeking to divest, the firm guides them through the intricate sell-side process, which includes valuation, market positioning, negotiation, and deal closure, with the goal of securing optimal outcomes for the seller. On the buy-side, Nelson Advisors assists clients in identifying, evaluating, and ultimately acquiring suitable HealthTech companies that align with their strategic objectives and growth mandates. Beyond traditional M&A, the firm's services extend to corporate divestitures, strategic partnerships, and portfolio optimization. The firm helps clients sell non-core assets or business units to liberate capital for reinvestment in higher-growth areas. The firm also provides investment-related advisory services, such as fundraising and commercial due diligence, demonstrating a role that goes beyond transactional execution to include strategic capital planning and partnership formation. A unique service offering is Tech Asset Sales, where the firm facilitates the sale of discrete technology assets, acknowledging the value of intellectual property and specific technological components that companies may wish to monetise or divest. Strategic Emphasis on Early-Stage Exits and Market Context A key aspect of the firm’s M&A services is its specific focus on Seed/Series A exits for early-stage companies.This is a highly strategic and market-responsive service. The firm acknowledges the increasing trend for early-stage HealthTech companies to find M&A as a primary exit route. This trend is driven by a tighter venture capital funding environment and a less active IPO market, making such exits a necessary outcome rather than an optional path. The firm's expertise and network are particularly valuable for these clients, as they can efficiently navigate the complex process of finding a strategic buyer and maximising value in a challenging capital market environment. Nelson Advisors also positions itself as a thought leader in the industry, evidenced by its publication of a market report on the European HealthTech M&A landscape. This report provides valuable context, noting a "cautious yet discernible rebound" in 2025 characterised by a "flight to quality," where deal values are increasing despite a decline in the number of transactions. The report attributes this to substantial private equity "dry powder" and the transformative influence of emerging technologies, particularly Artificial Intelligence. This publication reinforces the firm's expertise and credibility, positioning it as an authority in its field. Leadership, Expertise, and the "Founders for Founders" Approach Founding Partners' Professional Biographies Nelson Advisors' leadership is comprised of two founding partners, Lloyd Price and Paul Hemings, whose combined professional backgrounds represent a unique, dual-faceted expertise. This complementary skill set is the cornerstone of the firm's credibility and a significant competitive differentiator. Lloyd Price, a Partner and Co-Founder, brings more than 12 years of hands-on entrepreneurial experience as a successful HealthTech founder. He founded and successfully exited several companies, including Zesty in 2020, which was sold to a FTSE-listed company. Prior to his HealthTech career, he held senior roles in business development, marketing, and strategy at major technology firms like Yahoo! Europe and Badoo/Bumble. He is also actively involved in the ecosystem as a Health Executive in Residence at the UCL Global Business School for Health and as a judge for industry awards. Paul Hemings, also a Partner and Co-Founder, offers a decade of global M&A and capital raising expertise, complementing Price’s entrepreneurial background. He previously worked in senior investment banking advisory roles at Credit Suisse, where his transaction experience included over $50 billion in M&A deals and $40 billion in equity/financing transactions across a wide range of countries. Paul also has entrepreneurial experience, having founded and exited two early-stage companies, most recently in metabolic HealthTech. His educational background includes an MBA from the London Business School and an honors degree in Economics from Queen’s University in Canada. The collective expertise of the founders forms a powerful combination: the deep, operational knowledge of a successful founder and the extensive, high-level corporate finance perspective of a seasoned investment banker. This unique blend allows the firm to offer a highly strategic and comprehensive advisory service. The "Founders for Founders" Value Proposition The firm’s distinct "Founders for Founders" approach is central to its brand and market positioning. This model is not just a marketing slogan; it is a fundamental aspect of how the firm operates. The founding partners have personally "built, pivoted and scaled HealthTech businesses," and this firsthand entrepreneurial experience provides a profound and empathetic understanding of the HealthTech ecosystem. For clients, this approach translates into a unique advisory experience. The partners have walked in their clients’ shoes, enduring the challenges of securing funding, navigating market shifts, and ultimately pursuing a successful exit. This shared experience fosters a level of trust and strategic alignment that is difficult for generalist advisory firms to replicate. The advisors can offer guidance that goes beyond financial metrics to encompass the operational, psychological, and strategic complexities of the founder's journey. This deep, client-centric understanding is a key psychological and strategic differentiator, allowing Nelson Advisors to provide tailored solutions that a traditional banker might overlook because they lack this personal, lived experience. Market Positioning and Competitive Landscape Differentiation from Generalist M&A Firms and Investment Banks Nelson Advisors' market positioning is defined by its strategic choice to compete on depth of specialization rather than on sheer scale or volume. The firm’s status as "one of Europe's leading" M&A advisory firms is derived from its deep niche expertise, not from being a top-tier generalist ranked by overall M&A volume or value. Major global and European M&A players, such as Goldman Sachs, PwC, Rothschild & Co, UBS, and Houlihan Lokey, are frequently found in league tables based on total deal value or volume across all industries. Nelson Advisors is not typically found among these top-tier generalist advisors. This is not an indication of a lack of success; rather, it is a deliberate competitive strategy. By carving out a defensible and highly valuable niche in HealthTech, Nelson Advisors avoids direct competition with these giants on their home turf. The firm's "granular understanding" and "tailored approach" provide a distinct competitive advantage over generalist firms, who may have to hire outside experts or rely on broad knowledge bases when navigating the complexities of the HealthTech sector. This nuanced leadership is a qualitative advantage that distinguishes it from a purely quantitative, volume-based leadership model. Broader Market Context and Strategic Alignment The firm's strategy is perfectly aligned with the prevailing dynamics of the European HealthTech M&A market. The firm’s own market report provides a macro-level view, indicating a "cautious yet discernible rebound" in 2025. This resurgence is driven by improving macroeconomic conditions, significant private equity dry powder, and a strategic imperative for digital transformation across the healthcare ecosystem. The market is characterised by a "flight to quality," where increasing deal values are observed despite a decline in deal counts. This trend directly benefits a firm with Nelson Advisors' deep specialisation, as it can accurately identify and value high-quality assets for its clients. The availability of substantial private equity capital creates a strong demand side for the firm’s sell-side mandates. Furthermore, Nelson Advisors’ focused expertise in AI and Cybersecurity is a direct response to the "transformative impact of emerging technologies".This positioning makes them an ideal partner for the companies that are driving this market transformation, which must also navigate the specific complexities of the regulatory landscape. The firm is not merely a participant in the market; its strategy is an intelligent and deliberate response to its most critical dynamics. Sophisticated and highly specialised boutique investment banking firm The analysis of Nelson Advisors reveals a sophisticated and highly specialised boutique investment banking firm whose value proposition is built on a unique confluence of expertise. The firm's exclusive focus on the European HealthTech sector is a powerful competitive differentiator, allowing it to provide a level of nuanced, industry-specific advisory that generalist firms cannot match. The "Founders for Founders" approach, which is the cornerstone of its identity, is a strategic asset that provides a deeper, more empathetic understanding of client needs. This model, combined with the complementary entrepreneurial and corporate finance backgrounds of its founding partners, positions the firm as a trusted advisor capable of navigating the complex landscapes of M&A, partnerships, and investment advisory. Nelson Advisors’ strategic alignment with current market trends is evident in its focus on high-growth sub-sectors like AI and Cybersecurity, and its specialization in early-stage M&A exits. This approach demonstrates a forward-thinking business model designed to thrive in a market characterized by a "flight to quality" and shifting capital dynamics. While the firm's advisory track record is not publicly disclosed, the credibility of its leadership is built on a verifiable history of founding and successfully exiting multiple HealthTech companies. This expertise, combined with its thought leadership through published market reports, solidifies its standing as a leading authority within its specialised niche. For professional audiences, it is essential to recognize these distinctions and to understand that the firm's leadership is a qualitative one, based on the depth of its expertise, rather than a quantitative one based on broad market share. Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising#BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk